document incorporate reference incorporate scheringplough corporation proxy statement annual meeting shareholder iiitable content age item business item risk factor item unresolved staff comment item property item legal proceeding item submission matter vote security holder executive officer registrant item market registrant common equity relate stockholder matter item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure management report internal control financial reporting iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item principal accountant fee service item exhibit financial statement schedule report form signature exexii saving advantage plan exl retirement benefit equalization plan computation ratio earning fix charge subsidiary registrant consent deloitte touche llp independent auditor consent power attorney certification certification certification certificationtable content item business overview business scheringplough company refer scheringplough corporation subsidiary indicate context schering corporation predecessor company incorporate new york new jersey trademark indicate capital letter property license promote distribute scheringplough corporation subsidiary relate company scheringplough global sciencebase health care company lead prescription consumer animal health product internal research collaboration business partner scheringplough discover develop manufacture market advanced drug therapy meet important medical need scheringplough vision earn trust physician patient customer shareholder serve world scheringplough worldwide headquarters kenilworth new jersey website wwwscheringploughcom april board director name fred hassan new chairman board chief executive officer scheringplough corporation leadership eightyear action agenda plan direct goal stabilize repair turn scheringplough produce longterm value shareholder establish new leadership team recruit segment information new management team reorganize business manage geographic line primary segment restofworld business organize product currently scheringplough reportable segment prescription pharmaceutical consumer health care animal health segment sale profit datum follow consistent scheringplough current management reporting structure prescription pharmaceutical prescription pharmaceutical segment discover develop manufacture market human pharmaceutical product prescription pharmaceutical segment customer group primary care specialty care cholesterol franchise principal product segment include primary care allergy respiratory nasonex oncedaily nasalinhale steroid nasal allergy symptom include congestion treatment nasal polyp patient year age old clarinex nonsedate antihistamine treatment allergic rhinitis foradil aerolizer longacting betaagonist market scheringplough united states maintenance treatment asthma chronic obstructive pulmonary disease acute prevention exerciseinduce bronchospasm asmanex twisthaler oral drypowder corticosteroid inhaler firstline maintenance treatment asthma antibiotic avelox broadspectrum fluoroquinolone antibiotic certain respiratory skin infection cipro broadspectrum fluoroquinolone antibiotic certain respiratory skin urinary tract infection dermatological elocon mediumpotency topical steroid cream lotion ointment disorder levitra phosphodiesterase type inhibitor pde comarketed scheringplough united states treatment male erectile dysfunction table content specialty care antiviral pegintron powder injection pegylate interferon product chronic hepatitis approve dosing accord patient body weight intron injection chronic hepatitis antiviral indication rebetol capsule use pegintron intron chronic hepatitis antiinflammatorie remicade antitnf antibody market scheringplough outside united states treatment rheumatoid arthritis crohns disease ankylose spondylitis psoriatic arthritis psoriasis firstline therapy treatment early rheumatoid arthritis oncology temodar capsule certain type brain tumor include newly diagnose glioblastoma multiforme caelyx longcirculating pegylate liposomal formulation cancer drug doxorubicin market scheringplough outside united states treatment certain ovarian cancer kaposis sarcoma metastatic breast cancer intron injection market numerous anticancer indication worldwide include adjuvant therapy malignant melanoma acute coronary care integrilin injection platelet receptor iib iiia inhibitor treatment patient acute coronary syndrome undergo percutaneous coronary intervention united states prevention early myocardial infarction patient acute coronary syndrome country disorder subutex sublingual tablet formulation buprenorphine suboxone sublingual tablet combination buprenorphine naloxone market scheringplough certain country outside united states treatment opiate addiction cholesterol franchise zetia novel cholesterolabsorption inhibitor discover scheringplough scientist use combination statin drug monotherapy low cholesterol vytorin cholesterollowere tablet combine dual action zetia merck inc statin zocor consumer health care consumer health care segment develop manufacture market otc foot care sun care product principal product segment include overthecounter product claritin nondrowsy antihistamine drixoral cold allergy allergy sinus flu nasal decongestant tablet afrin nasal decongestant spray correctol laxative tablet foot care scholl foot care product lotrimin topical antifungal product tinactin topical antifungal product foot sneaker odorwetness product sun care coppertone sun care lotion spray dry oil lipprotection product sunless tanning product solarcaine sunburn relief product animal health animal health segment discover develop manufacture market animal health product principal product segment include livestock product nuflor bovine swine antibiotic banamine bovine swine antiinflammatory mpac swine pneumonia vaccine poultry product paracox coccivac coccidiosis vaccine poultry table content companion animal product otomax steroid otitis dog exspot topical insecticide dog homeagain pet recovery service zubrin antiinflammatory analgesic dog aquaculture product slice parasiticide sea lice salmon aquaflor antibiotic farmraised fish net sale segment de decem ber dollar million prescription pharmaceutical consumer health care animal health consolidate net sale profit segment de decem ber dollar million prescription pharmaceutical consumer health care animal health corporate consolidated profitloss tax corporate include interest income expense foreign exchange gain loss headquarters expense special charge miscellaneous item accounting policy segment report describe note summary significant accounting policy item financial statement supplementary datum corporate include special charge million include million employee termination cost million asset impairment charge increase litigation reserve million result total reserve million represent company current estimate resolve massachusetts investigation investigation disclose awp investigation state litigation disclose awp litigation note legal environmental regulatory matter item financial statement supplementary datum estimate charge relate reportable segment follow prescription pharmaceutical million consumer health care million animal health million corporate million corporate include special charge million include million employee termination cost million asset impairment charge estimate charge relate reportable segment follow prescription pharmaceutical million consumer health care million animal health million corporate million corporate include special charge million include million employee termination cost million provision increase litigation reserve million asset impairment charge estimate charge relate reportable segment follow prescription pharmaceutical million consumer health care million animal health million corporate million table content note special charge item financial statement supplementary datum additional information global operation nonus operation generate majority company profit cash flow nonus activity carry primarily whollyowne subsidiary market potential adequate circumstance permit addition scheringplough represent market licensee distribution arrangement currently scheringplough business operation country approximately employee outside nonus operation subject certain risk inherent conduct business overseas risk include possible nationalization expropriation importation limitation pricing reimbursement restriction restrictive governmental action economic destabilization fluctuation foreign currency exchange rate impact scheringplough consolidated financial result additional information global operation item management discussion analysis financial condition result operation segment information describe net sale geographic area dollar millions united states europe canada pacific area asia latin america consolidated net sale company subsidiary country outside single international country france japan italy account percent consolidated net sale past year net sale present geographic area company customer locate consolidated net consolidated net consolidated net sale net sale sale net sale sale net sale llar million total international net sale france japan italy net sale customer consolidate net consolidated net consolidated net sale net sale sale net sale sale net sale dol lars millions mckesson corporation single customer mckesson corporation major pharmaceutical health care product distributor account percent consolidated net sale past year table content longlive asset geographic location dollar millions united states singapore ireland puerto rico total longlive asset show geographic location primarily property supplemental sale information sale product comprise percent company international sale year end december follow amo unt perce ntage dollar million nasonex otc claritin international remicade pegintron scheringplough net sale include sale vytorin zetia market partnership merck company account joint venture equity method accounting note equity income cholesterol joint venture item financial statement supplementary datum company disaggregate asset segment basis internal management report information present research development scheringplough research activity primarily aim discover develop new prescription product enhancement exist prescription product medical commercial significance companysponsore research development expenditure million million million respectively research expenditure represent approximately percent consolidated net sale percent consolidate net sale approximately percent consolidated net sale scheringplough research activity concentrate therapeutic area respiratory disease inflammatory disease infectious disease oncology cardiovascular metabolic disease central nervous system disorder scheringplough substantial effort direct biotechnology immunology research activity include expenditure internal research effort research collaboration partner pharmaceutical compound vary stage development predict compound available commercial sale company product pipeline list significant product development available scheringplough website wwwscheringploughcom table content patent trademark intellectual property right overview intellectual property protection critical scheringplough ability successfully commercialize product innovation scheringplough own apply license right large number patent country relate molecule product product use formulation manufacturing process assurance patent scheringplough seeking grant patent scheringplough grant find valid challenge patent relate particular molecule product use formulation process preclude manufacturer employ alternative process market alternative product formulation successfully compete company patent product outside standard intellectual property protection pharmaceutical vary widely country reasonably strong patent law country currently provide little effective protection invention intellectual property right traderelate aspect intellectual property agreement trip administer world trade organization wto country agree provide nondiscriminatory protection pharmaceutical invention assure adequate effective right available patent owner possible change agreement future diminish delay implementation develop country soon assess company impact commercially change product patent expire patent holder lose effective market exclusivity product result rapid sharp material decline sale patent product particularly case innovator company obtain additional commercial benefit manufacture trade secret laterexpire patent process use formulation trademark use exclusivity available pharmaceutical regulatory law scheringplough intellectual property portfolio patent protection certain scheringplough molecule product process use important scheringploughs business financial result company product addition patent compound scheringplough hold patent manufacturing process formulation use extend exclusivity expiration compound patent scheringplough subsidiary license right number patent patent application abroad patent patent application relate scheringplough significant product include limitation vytorin zetia remicade nasonex intron pegintron temodar clarinex material importance scheringplough worldwide scheringplough sell major product trademark material aggregate business financial result trademark protection vary world protection continue country long mark country long register registration normally fix renewable term patent challenge hatchwaxman act drug price competition patent term restoration act commonly know hatchwaxman complex set change patent new drug approval law hatchwaxman drug approve provide food drug administration fda complete safety efficacy study know complete new drug application nda hatchwaxman authorize fda approve generic version innovative medicine information file abbreviate new drug application anda anda generic manufacturer demonstrate bioequivalence generic version ndaapprove drug safety efficacy hatchwaxman provide limited patent term restoration partially patent term lose time ndaapprove drug regulatory review ndaapprove drug receive limited period datum exclusivity prevent approval anda application specific time period approval nda approve drug table content absent successful patent challenge fda approve anda innovators patent expire generic manufacturer file anda seek approval expiration applicable datum exclusivity allege patent list innovators nda invalid infringe allegation commonly know paragraph certification innovator file suit generic manufacturer protect patent ndaliste patent successfully challenge fil paragraph certification entitle day period market exclusivity generic manufacturer recent year generic manufacturer paragraph certification extensively challenge patent wide array innovative pharmaceutical anticipate trend continue marketing activity competition prescription drug introduce known physician pharmacist hospitals manage care organization buy group train professional sale representative sell hospital certain manage care organization wholesale distributor retail pharmacist prescription product introduce known journal advertise direct mail advertising distribution sample physicians television radio internet print advertising medium animal health product promote veterinarian distributor animal producer footcare otc suncare product sell wholesale retail drug food chain mass merchandiser outlet promote directly consumer television radio internet print advertising media pharmaceutical industry highly competitive include large company significantly large scheringplough substantial resource research product development advertising promotion field sell support numerous domestic international competitor industry principal competitive technique scheringplough product include research development new improve product vary dosage form strength switch prescription product nonprescription status scheringploughs product subject increasingly competitive pricing manage care group institution federal state government entity agency buy group seek price discount rebate governmental pressure dispense generic product significantly reduce sale certain product compete product therapeutic category long protect patent exclusivity available pharmaceutical regulatory law scheringplough operate primarily prescription pharmaceutical marketplace appropriate scheringplough seek future seek regulatory approval switch prescription product overthecounter otc status mean extend product life cycle way otc marketplace mean maximize return investment discovery development government regulation company major business segment subject significant regulation multiple jurisdiction section describe general regulatory framework additional information cost regulatory compliance specific impact companys business financial condition describe head regulatory competitive environment company operate management discussion analysis later additional information regulatory matter find item legal matter note consent decree note legal environmental regulatory matter item financial statement supplementary datum prescription drug segment regulation apply phase business include regulatory requirement conduct standard clinical trial example require use good clinical practice gcp apply research development stage table content regulatory requirement conduct standard postapproval clinical trial require regulatory approval begin market new drug market exist drug product new indication regulation prescribe manner drug manufacture package label advertise market distribute regulation impact pricing drug regulatory requirement assess report adverse impact effect drug clinical trial market drug call pharmacovigilance ability regulatory authority remove product market recall certain batch product national regulation phase prescription drug business price centralize food drug administration fda fda responsible protect public health assure safety efficacy security human veterinary drug biological product medical device generally free market pricing center medicare medicaid services cms medicare include provision price drug elderly disabled indigent receive federal prescription benefit company commit comply voluntary good practice pharmaceutical research manufacturers america phrma trade industry group member marketing advertising practice european union include company key market united kingdom france germany italy regulation local country level additional regulation level european medicine agency emea pharmaceutical product regulate level national mutual recognition centralized regulatory procedure emea coordinate evaluation supervision medicinal product european union paneu market pricing system individual member state systemsagencie regulate price local level japan regulation pharmaceutical medical device agency pmda pmda regulate pharmaceutical medical device development postmarketing use japanese government regulate pricingreimbursement pharmaceutical product japan complicated pricing process include benchmark price western country united states canada select country major country influence pricing cms united states increase pressure pharmaceutical industry bring product market provide differentiation versus exist product lead expensive scientifically challenging clinical trial order generate type datum new product versus market comparator information merck scheringplough joint venture company merck inc merck enter separate set agreement jointly develop market certain product include cholesterollowere drug allergyasthma drug december cholesterol agreement expand include country world japan general company agree collaborative activity agreement operate virtual joint venture maximum degree possible rely respective infrastructure company agreement generally provide equal sharing development cost copromotion approve product company table content cholesterol agreement provide company merck jointly develop ezetimibe market zetia asia ezetrol europe oncedaily monotherapy coadministration statin drug iii oncedaily fixedcombination tablet ezetimibe simvastatin zocor merck cholesterolmodifye medicine combination medication ezetimibesimvastatin market vytorin inegy international country zetia ezetrol ezetimibe vytorin inegy combination ezetimibesimvastatin approve use launch international market company utilize equity method account joint venture cholesterol agreement provide share net incomeloss base percentage vary product sale level country market scheringplough receive great share profit million annual zetia sale million annual zetia sale merck scheringplough partner share profit equally scheringplough allocation joint venture income increase milestone earn partner share joint venture net incomeloss subject reduction partner fail perform specify minimum number physician detail particular country partner agree annually minimum number physician detail country partner bear cost general sale force commercial overhead marketing joint venture product world canada puerto rico cholesterol agreement provide reimbursement partner physician detail set annual basis reimburse equal partner physician detail multiply contractual fix fee scheringplough report receipt reimbursement equity income cholesterol joint venture represent reimbursement specific incremental identifiable cost company detail cholesterol product market addition reimbursement reflective scheringplough sale effort relate joint venture scheringplough sale force relate cost associate joint venture generally estimate high cost joint venture partner contractually share portion manufacturing cost specifically identify promotion cost include directto consumer advertising direct identifiable outofpocket promotion agreedupon cost specific service market support market research market expansion specialty sale force physician education program certain specify research development expense generally share equally partner virtual nature cholesterol joint venture company incur substantial cost sell general administrative cost reflect equity income cholesterol joint venture bear overall cost structure company cost report respective line item statement consolidated operation cholesterol agreement provide jointly own facility product result collaboration manufacture facility own company merck allergyasthma agreement provide joint development marketing partner oncedaily fixedcombination tablet contain claritin singulair singulair merck oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis january merck scheringplough respiratory joint venture report result phase iii clinical trial fixedcombination tablet contain claritin singulair phase iii study demonstrate sufficient add benefit treatment seasonal allergic rhinitis claritin singulair combination tablet approval country remain clinical development new phase iii clinical trial plan table content raw material raw material essential scheringplough available adequate quantity number potential supplier energy expect available scheringplough sufficient quantity meet operating requirement seasonality certain company product particularly respiratory suncare category seasonal nature seasonal pattern pronounce effect consolidated operation scheringplough environment date compliance federal state local law discharge material environment protection environment material effect scheringploughs capital expenditure earning competitive position employee approximately people employ scheringplough december available information scheringplough amendment report file sec available free charge scheringplough website soon reasonably practicable material electronically file sec scheringploughs address world wide web wwwscheringploughcom scheringplough begin practice quarter report available scheringplough website hour filing report file scheringplough sec read copy secs public reference room street washington information operation public reference room obtain call sec sec sec maintain internet site wwwsecgov contain report proxy information statement information issuer file electronically sec item risk factor companys future operating result cash flow differ materially result describe risk uncertaintie relate company business include discuss addition factor represent risk uncertainty cause actual result differ materially imply forwardlooke statement contain report key company product generate significant company profit cash flow event adversely affect market lead product material negative impact result operation cash flow company ability generate profit operate cash flow dependent increase profitability company cholesterol franchise consist vytorin zetia addition product clarinex pegintron rebetol remicade temodar otc claritin nasonex account material portion revenue result company dependence key product event adversely affect market product significant impact result operation event include loss patent protection increase cost associate manufacturing otc availability company product competitive product discovery previously unknown effect increase competition introduction new effective treatment discontinuation removal market product reason table content specifically profitability company cholesterol franchise adversely affect introduction generic form compete cholesterol product lose patent protection addition generic flonase fluticasone propionate approve unfavorably impact corticosteroid nasal spray market past example event recent year adversely affect market lead product include event affect market clarinex pegintron rebetol particularly clarinex continue experience intense competition prescription allergy market launch claritin otc compete otc loratadine product december introduction generic allegra fexofenadine september addition result introduction competitor product pegylate interferon introduction generic ribavirin value pegintron pegylate interferon rebetol ribavirin combination therapy hepatitis severely diminish earning cash flow materially negatively impact high risk fund invest research generate financial return development novel drug require significant expenditure low probability success high rate failure inherent research develop new drug treat disease result high risk fund invest research program generate financial return risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase market decade failure occur point process include later process significant fund invest company success dependent development marketing new product uncertaintie regulatory approval process result failure product reach market product appear promise development fail reach market numerous reason include follow finding ineffectiveness harmful effect clinical preclinical testing failure receive necessary regulatory approval include delay approval new product new indication lack economic feasibility manufacturing cost factor preclusion commercialization proprietary right intellectual property protection important contributor company profitability patent cover company product expire find invalid generic form company product introduce market material negative affect result operation intellectual property protection critical scheringplough ability successfully commercialize product expiration successful challenge company patent cover product competitor introduce generic version product include company table content establish product generic competition result loss significant portion sale downward pressure price company offer patent product particularly patent patent application relate scheringplough significant product material importance scheringplough additionally certain foreign government indicate compulsory license patent grant case national emergency diminish eliminate sale profit region negatively affect company result operation patent dispute costly prosecute defend adverse judgment result damage award increase royalty similar payment decrease sale patent position highly uncertain patent dispute pharmaceutical industry unusual adverse result patent dispute involve company patent lead loss market exclusivity render company patent invalid adverse result patent dispute involve patent hold party preclude commercialization company product force company obtain license order continue manufacture marketing affect product negatively affect sale exist product result injunctive relief payment financial remedy example company product scholl freeze away wart removal product currently subject patent infringement action bring party company adverse outcome action result company inability continue manufacture product company ultimately successful particular dispute company incur substantial cost defend patent intellectual property right example generic manufacturer file abbreviate new drug application seek approval expiration applicable datum exclusivity allege patent list innovator new drug application invalid infringe allegation commonly know paragraph certification innovator ability file suit generic manufacturer enforce patent recent year generic manufacturer paragraph certification extensively challenge patent wide array innovative pharmaceutical anticipate trend continue potential litigation scheringploughs intellectual property right exist initiate party attempt abridge scheringplough right scheringplough protect right foreign regulation include establish company ability price product negatively affect company sale profit margin company face increase pricing pressure abroad manage care organization institution government agency program negatively affect company sale profit margin example medicare prescription drug improvement modernization act contain prescription drug benefit individual eligible medicare prescription drug benefit effective january anticipate result increase purchasing power negotiating behalf medicare recipient addition legislation concern price control trend affect company business include legislative regulatory action relate pharmaceutical pricing reimbursement health care reform initiative drug importation legislation involuntary approval medicine otc use consolidation customer trend manage care health care cost containment result government effort reduce medicaid expense manage care organization continue grow influence company face increase pricing pressure manage care organization continue seek price discount respect company product international market cost control method include restriction physician prescription level patient reimbursement emphasis great use generic drug board price cut decrease revenue internationally table content material pende investigation company outcome include commencement civil andor criminal proceeding involve imposition substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program company predict certainty outcome pende investigation subject lead judgment settlement involve significant monetary award restriction operation pricing sale marketing program arrangement relate business practice company participant health care industry increase scrutiny federal state regulatory investigative prosecutorial administrative entity entity include department justice attorney office office inspector general department health human service fda federal trade commission state attorney general office health care law certain governmental entity operate include federal state anti kickback statute statutory common law false claim law construe broadly court permit government entity exercise significant discretion event governmental entity believe wrongdoing occur institute civil criminal proceeding institute resolve unfavorably subject company substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program company predict investigation affect marketing practice sale result material adverse impact company result operation cash flow financial condition business regardless merit outcome investigation government investigation costly divert management attention company business result substantial damage company reputation refer item legal proceeding report description pende investigation legal matter adverse outcome negatively affect company business unfavorable outcome pende litigation matter include litigation concern product pricing security law violation product liability claim erisa matter patent intellectual property dispute antitrust matter preclude commercialization product negatively affect profitability exist product materially adversely affect company financial condition result operation subject company condition affect business operation exclusion government reimbursement program refer item legal proceeding report description significant pende litigation company subject governmental regulation failure comply cost compliance regulation adversely affect company financial position result operation company manufacture facility meet stringent regulatory standard subject regular inspection cost regulatory compliance include associate compliance failure materially affect company financial position result operation failure comply regulation include pharmacovigilance reporting requirement standard relate clinical laboratory manufacturing practice result delay approval drug seizure recall drug suspension revocation authority necessary production sale drug fine civil criminal sanction example company agree fda entry consent decree resolve issue relate compliance current good manufacturing practice certain company facility new jersey puerto rico consent decree work place significant additional control production release product site increase cost table content slow production lead reduction number product produce site companys research development operation negatively impact consent decree operation share common facility manufacturing operation company subject regulation include environmental health safety labor regulation development follow regulatory approval decrease demand company product product reach market certain development follow regulatory approval decrease demand company product include follow rereview product market uncertainty concern safety labeling change great scrutiny advertising promotion recently clinical trial postmarkete surveillance certain market drug competitor industry raise safety concern lead recall withdrawal adverse labeling market product situation raise concern prescriber patient relate safety efficacy pharmaceutical product general negatively affect sale product addition follow wake recent product withdrawal company significant safety issue health authority fda european medicine agency pharmaceutical medicine device agency increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication review select product market add uncertainty regulatory process great regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown effect discover increase prevalence negative publicity know effect company product significantly reduce demand product require company remove product market new product technological advance develop companys competitor negatively affect sale company operate highly competitive industry company competitor conduct research development area serve company current product product company process develop competitive development impact company include technological advance patent grant new product develop competitor new exist generic prescription andor otc product compete product scheringplough merck scheringplough cholesterol partnership addition possible doctor patient provider favor product offer competitor safety efficacy pricing reimbursement characteristic result company unable maintain sale product company compete company acquire license product early stage development approve commercial sale company believe clinically commercially attractive difficult company enter transaction aspect company business acquire license right develop sell product company challenge acquire license product company believe clinically commercially attractive acceptable term company compete opportunitie company far great financial resource company company prospect adversely affect unable obtain right additional product acceptable term table content company rely party relationship key product change party outside control impact business company rely party relationship key product time party involve change influence impact party outside control company directly indirectly impact company business operation company operational financial control party limit influence respect manner conduct business behave relationship company case party offer develop product compete company product conflict interest relative company company operate global business expose company additional risk adverse event material negative impact result operation company operate country nonus operation generate majority company profit cash flow nonus operation subject certain risk inherent conduct business overseas risk include possible nationalization expropriation importation limitation pricing reimbursement restriction restrictive governmental action economic destabilization fluctuation inflation interest rate foreign currency exchange rate impact scheringplough consolidated financial result addition change company business political position instability disruption destruction significant geographic region regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease insurance coverage product liability unavailable cost prohibitive company maintain insurance coverage deductible selfinsurance reflect market condition include cost availability exist time write relationship insurance coverage selfinsurance vary accordingly result increase product liability claim pharmaceutical industry availability party insurance unavailable cost prohibitive company subject evolve complex tax law result additional liability affect result operation company subject evolve complex tax law foreign jurisdiction significant judgment require determine company tax liability company tax return periodically examine tax authority company federal income tax return period currently audit internal revenue service company challenge irs tax authority position take income tax return company believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority complexity tax contingency ultimate resolution result payment materially affect shareholder equity liquidity andor cash flow addition company impact change tax law include tax rate change new tax law revise tax law interpretation domestic foreign jurisdiction table content item unresolved staff comment item property scheringplough corporate headquarters locate kenilworth new jersey principal research facility locate kenilworth union summit new jersey palo alto california elkhorn nebraska principal manufacturing facility follow location product type kenilworth new jersey pharmaceutical consumer product omaha nebraska animal health cleveland tennessee consumer products puerto rico pharmaceuticals belgium pharmaceuticals ireland pharmaceutical consumer product animal health mexico pharmaceuticals singapore pharmaceutical company anticipate capital expenditure million year pharmaceutical sciences center item legal proceeding material pende legal proceeding ordinary routine litigation incidental business scheringplough corporation subsidiary property subject disclose additional information legal proceeding include important financial information find litigation charge discussion note special charge note legal environmental regulatory matter contain item financial statement supplementary datum item management discussion analysis financial condition result operation patent matter describe patent trademark intellectual property right business intellectual property protection critical scheringplough ability successfully commercialize product innovation potential litigation scheringploughs intellectual property right exist initiate party attempt abridge scheringplough right scheringplough protect right patent matter describe potential material effect company scholl freeze away patent july orasure technology file action district court eastern district pennsylvania allege patent infringement scheringplough healthcare product sale scholl freeze away wart removal product complaint seek permanent injunction unspecified damage include treble damage investigation massachusetts investigation attorney office district massachusetts investigate broad range company sale marketing clinical trial practice program warrick pharmaceuticals warrick companys generic subsidiary investigation focus follow allege practice provide remuneration manage care organization physician induce purchase schering pharmaceutical product offlabel marketing drug submit false pharmaceutical pricing information government table content purpose calculate rebate require pay medicaid program company cooperate investigation outcome investigation include commencement civil andor criminal proceeding involve imposition substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program company record liability million relate investigation investigation describe awp investigation state litigation describe awp litigation reasonably possible settlement investigation involve amount materially excess accrual awp investigation company continue respond exist new investigation department health human services department justice state industry company practice average wholesale price awp investigation relate awp pharmaceutical company certain drug improperly exceed average price pay provider consequence result unlawful inflation certain government drug reimbursement base awp company cooperate investigation outcome investigation include imposition substantial fine penalty injunctive administrative remedy nitrodur investigation august company receive civil investigative subpoena issue office inspector general department health human service seek document concern company classification nitrodur medicaid rebate purpose company use nominal pricing bundle product sale company cooperate investigation appear subpoena number address pharmaceutical company concern inquiry issue relate payment government rebate pricing matter awp litigation company continue respond exist new litigation certain state private payor industry company practice average wholesale price awp litigation relate awp pharmaceutical company certain drug improperly exceed average price pay provider consequence result unlawful inflation certain reimbursement drug state program private payor base awp complaint allege violation federal state law include fraud medicaid fraud consumer protection violation claim majority case plaintiff seek class certification case class certify outcome litigation include substantial damage imposition substantial fine penalty injunctive administrative remedy security class action litigation federal security litigation follow company announcement fda conduct inspection company manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current good manufacturing practice lawsuit file company certain name officer lawsuit allege defendant violate federal security law allegedly fail disclose material information make material misstatement specifically allege company fail disclose allege risk new drug application clarinex delay result manufacturing issue allege company fail disclose allege depth severity manufacturing issue complaint consolidate action district court district new jersey consolidated amend complaint file october purport represent class shareholder purchase share company stock february complaint seek compensatory damage behalf class court certify shareholder class october discovery ongoing shareholder derivative action lawsuit file district court district new jersey company certain officer director director seek damage table content behalf company include disgorgement trading profit defendant allegedly obtain basis material nonpublic information complaint allege failure disclose material information breach fiduciary duty director relate fda inspection investigation company pricing practice sale marketing clinical trial practice lawsuit shareholder derivative action purport assert claim behalf company shareholder derivative action pende district court district new jersey consolidate action august early stage product liability company previously disclose defendant putative class action lawsuit involve alleged claim personal injury arise plaintiff ingestion phenylpropanolaminecontaine coughcold remedy ppa product class action lawsuit plaintiff assert claim personal injury arise use laxative product seek refund purchase price laxative purchase lawsuit dismiss resolve amount pay resolve matter immaterial class action lawsuit currently exist concern ppa claim individual lawsuit involve ppa product pende company deem pende lawsuit immaterial aggregate company previously disclose defendant individual lawsuit relate recall albuterol vanceril vancenase inhaler lawsuit dismiss resolve amount pay resolve lawsuit immaterial erisa litigation march company serve putative class action complaint file district court new jersey allege company retire chairman ceo president richard jay kogan company employee saving plan plan administrator current director certain corporate officer messrs larosa moore breach fiduciary obligation certain participant plan complaint seek damage loss allegedly suffer plan complaint dismiss june plaintiff appeal august court appeal circuit reverse dismissal district court matter remand district court proceeding kdur antitrust litigation kdur scheringploughs longacting potassium chloride product supplement cardiac patient follow commencement ftc administrative proceeding describe allege class action suit file federal state court behalf direct indirect purchaser kdur scheringplough upshersmith lederle suit claim violation federal state antitrust law state statutory common law cause action suit seek unspecified damage discovery ongoing antitrust matter kdur scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle relate generic version dur lederle upsher smith file abbreviate new drug application april ftc start administrative proceeding scheringplough upshersmith lederle allege anticompetitive effect settlement administrative law judge issue decision patent litigation settlement comply law respect dismiss claim company ftc staff appeal decision commission commission reverse decision administrative law judge rule settlement violate antitrust law commission issue cease desist order impose injunctive restraint federal court appeal set aside commission rule vacate cease desist order august ftc file petition seek hear supreme court senate finance committee inquiry january united states senate committee finance follow previous request company request information company practice relate educational grant company understand committee direct similar followup request table content pharmaceutical company company cooperate committee process respond request tax matter october irs auditor assert interest rate swap company enter unrelated party recharacterize loan affiliate company result additional tax liability tax year september company payment irs million income tax million interest company file refund claim tax interest irs december follow irss denial company claim refund company file suit district court district new jersey refund tax interest refund litigation currently discovery phase company tax reserve adequate cover abovementione payment pende administrative obligation connection settlement investigation department justice attorney office eastern district pennsylvania company enter fiveyear corporate integrity agreement cia disclose note consent decree company subject obligation consent decree fda failure comply obligation cia consent decree result financial penalty discussion pende pharmacovigilance matter result pharmacovigilance inspection official british french medicine agency conduct request european agency evaluation medicinal product emea refer regulatory competitive environment company operate management discussion analysis matter biopharma contract dispute biopharma srl file claim civil court rome july docket chamber certain scheringplough subsidiary complaint allege scheringplough fulfill duty distribution supply agreement biopharma scheringplough subsidiary distribution scheringplough generic product manufacture biopharma hospital pharmacist france item submission matter vote security holder applicable table content executive officer registrant list executive officer corporate officer company indicate hold position indicate past year officer serve year successor duly appoint title robert bertolini executive vice president chief inancial officer ron cheeley senior vice president global human resource carrie cox executive vice president president global pharmaceuticals william creelman vice president tax douglas gingerella vice president controller fred hassan chairman chief executive officer thomas kelly vice president corporate business development raul kohan group head global specialty operation president animal health joseph larosa vice president legal affair ian mcinne senior vice president global supply chain kevin moore vice president treasurer cecil pickett phd senior vice president president scheringplough research institute division anne renahan vice president global internal audits thomas sabatino executive vice president general counsel karl salnoske vice president chief information officer brent saunder senior vice president global compliance business practice susan ellen wolf corporate secretary associate general counsel vice president corporate governance officer define rule securities exchange act bertolini join company executive vice president chief financial officer bertolini partner pricewaterhousecoopers cheeley join company senior vice president global human resources cheeley group vice president global compensation benefit pharmacia corporation cox join company executive vice president president global pharmaceuticals cox executive vice president president global prescription business pharmacia corporation table content creelman join company vice president tax creelman senior tax counsel pfizer creelman assistant vice president international tax cigna corporation vice president tax smithkline beecham gingerella name vice president controller gingerella vice president corporate audits hassan join company chairman board chief executive officer hassan chairman board chief executive officer pharmacia corporation kelly vice president corporate business development kelly vice president controller larosa vice president legal affair larosa staff vice president secretary associate general counsel mcinne join company senior vice president global supply chain mcinne senior vice president global supply chain pharmacia corporation executive vice president supply chain watson pharmaceuticals inc pickett name senior vice president pickett join scheringplough research institute executive vice president discovery research scheringplough research institute name president scheringplough research institute renahan join company vice president global internal audits renahan executive director controller eisai inc sabatino join company executive vice president general counsel sabatino senior vice president general counsel baxter international inc salnoske join company vice president chief information officer salnoske ceo adaptive trade saunder join company senior vice president global compliance business practice saunders partner pricewaterhousecooper wolf name vice president corporate secretary associate general counsel hold position scheringploughs law department senior attorney delta airline table content item market registrant common equity relate stockholder matter common share dividend share price datum approximate number holder record set forth item financial statement supplementary datum follow table provide information respect purchase company common share fourth quarter issuer purchase equity security tot number maxi mum number share purchase share average publicly purchase total number price pay announce plan plan period share purchase share program programs october throu october november november december december total october december share include table repurchase pursuant company stock incentive program represent share deliver company option holder payment exercise price tax withholding obligation connection stock option stock award table content item select financial datum llion exce sha figure percen tage operating result net sale incomeloss income taxis net incomeloss net incomeloss available common shareholder dilute earningsloss common share basic earningsloss common share research development expense depreciation amortization expense financial position cash flow property net total asset longterm debt shareholder equity capital expenditure financial statistic net incomeloss percent net sale return average shareholder equity net book value common share datum cash dividend common share cash dividend common share cash dividend prefer share average share outstanding calculate dilute earningsloss common share average share outstanding calculate basic earningsloss common share common share outstanding yearend include special charge respectively note special charge item financial statement supplementary datum additional information assume conversion prefer share approximately million common share million common share item management discussion analysis financial condition result operation executive summary overview company scheringplough company discover develop manufacture market medical therapy treatment enhance human health company market lead consumer brand overthecounter otc foot care sun care market operate global animal health business table content researchbase pharmaceutical company core strategy scheringplough invest substantial fund scientific research goal create therapy treatment important medical commercial value consistent core strategy company increase investment research development trend expect continue historic level great research development activity focus mechanism treat disease high rate failure inherent research result high risk fund invest research program generate financial return risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase commercial phase decade source new product product acquire acquisition licensing arrangement product company latestage research pipeline respect acquisition license limit opportunity obtain license critical latestage product limited opportunity typically require substantial amount fund company compete opportunitie company great financial resource accordingly challenge company acquire license critical latestage product positive material financial impact company support commercialize product manufacturing sale marketing effort company move forward additional investment enhance infrastructure business include capital expenditure development process product move drug discovery pipeline market information technology system postmarkete study monitor company financial situation continue improve discuss company cholesterol franchise product vytorin zetia primary driver improvement zetia company novel cholesterol absorption inhibitor vytorin combination zetia zocor merck inc merck statin medication product launch joint venture company merck zetia ezetimibe market europe ezetrol market use statin treatment elevate cholesterol level zetia ezetrol launch country vytorin ezetimibesimvastatin market inegy internationally launch country include united states company currently expect cholesterol franchise continue grow financial commitment compete cholesterol reduction market share merck profit sale vytorin zetia share merck operating result joint venture merck record equity method account outside joint venture merck japanese market bayer healthcare comarket company cholesterol absorption inhibitor zetia approval backlog new drug application japan company precisely predict timing approval cholesterolreduction market single large pharmaceutical category world vytorin zetia compete market combine basis product continue grow term market share franchise product capture percent new prescription cholesterol management market base january ims datum vytorin currently rank thirdleade prescription product treat patient high cholesterol base new prescription date physician write million total prescription vytorin zetia sale continue grow vytorin grow market share company result operation cash flow drive significantly performance vytorin zetia result company ability generate profit predominantly dependent performance vytorin zetia cholesterol franchise dependence expect continue time equity income cholesterol joint venture million net income available common shareholder million additional information joint venture merck include note equity income table content cholesterol joint venture item financial statement supplementary datum expect operate cash flow exist cash investment include fund repatriate american job creation act ajca fund company operation near intermediate term discuss detail future cash flow dependent performance vytorin zetia company generate profit cash flow maintain enhance infrastructure business discuss sale product impact introduction new innovative compete treatment generic version exist product regard company expect generic form pravachol zocor exist wellestablished cholesterolmanagement product introduce lose patent protection begin generic introduce international market company reasonably predict effect introduction generic form cholesterol management product vytorin zetia decision government entity manage care group group concern formulary reimbursement policy potentially negatively impact dollar size andor growth cholesterol management market include vytorin zetia material change sale market share vytorin zetia significant impact company operation cash flow remicade prescribe treatment rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylose spondylitis recently gain approval europe psoriasis remicade company second large market pharmaceutical product line cholesterol franchise product license manufactured centocor inc johnson johnson company company exclusive marketing right product outside japan china include hong kong taiwan indonesia quarter company exercise option contract centocor license right develop commercialize golimumab fully human monoclonal antibody territory remicade golimumab currently phase iii trial centocor believe right golimumab expire company believe right extend party work forward collaboration golimumab step take resolve difference opinion expiration date typical pharmaceutical industry company license manufacturing marketing andor distribution right certain product manufacture market andor distribute product own pursuant license joint venture arrangement time party involve additional factor relate party outside control company create positive negative impact company vytorin zetia remicade subject arrangement key company current business financial performance addition potential strategic alternative impact change control provision arrangement result vytorin zetia acquire merck remicade revert centocor change control provision relate vytorin zetia include contract merck file exhibit company change control provision relate remicade contain contract centocor file exhibit company period company experience number negative event strain continue strain company financial resource explain company overall financial situation begin improve negative event remain relevant understand company current challenge negative event include limited follow matter enter formal consent decree fda agree implement cgmp work plan revalidate manufacturing process certain manufacturing site puerto rico company complete significant step cgmp work plan validation action require december consent decree subject certification external party review approval fda term table content decree provide fda notify company significant violation fda law regulation decree year period decree entry company petition court decree dissolve fda oppose company petition company incur significant cost associate manufacturing compliance effort consent decree incremental compliance cost incur completion party certification fda review approval process addition company find necessary discontinue certain old profitable product outsource product switch claritin begin december prescription otc status switch couple private label competition result substantially low overall sale product start low average unit sell price product ongoing intense competition company exposure powerful retail purchaser increase market share sale level certain company product fall significantly experience increase competition product continue compete decline volatile market investigation certain company sale marketing practice attorney office massachusetts pennsylvania company payment total million attorney office eastern district pennsylvania settlement investigation response matter begin april board director name fred hassan new chairman board chief executive officer scheringplough corporation leadership new leadership team recruit eightyear fivephase action agenda formulate goal stabilize repair turn company october company announce enter turnaround phase action agenda begin turnaround phase define achieve consecutive quarter sale earning growth exclude special item current state business net sale billion increase billion percent period increase drive primarily growth remicade pegintron nasonex temodar animal health business sale contribution antibiotic avelox cipro product agreement bayer effective october foreign exchange contribute percent sale increase sale marketing cost increase addition bayer sale representative increase selling expense europe support continue launch vytorin zetia increase promotional spending primarily nasonex asmanex product agreement bayer company net income available common shareholder million compare net loss available common shareholder million net income available common shareholder include charge increase litigation reserve million result total reserve million represent company current estimate resolve massachusetts investigation investigation disclose awp investigation state litigation disclose awp litigation note legal environmental regulatory matter item financial statement supplementary datum addition net income available common shareholder include research development expense approximately million million net tax license right develop commercialize golimumab net loss available common shareholder include pretax research development charge million license garenoxacin toyama chemical company ltd tax expense million include table content provision taxis relate plan repatriation unremitte foreign earning american job creation act valuation reserve net defer tax asset company manufacture site operate capacity company manufacture site subject consent decree remain open company perform revalidation cgmp work plan obligation decree consent decree work place significant additional control production release product site increase cost slow production lead reduction product mix site company research development operation negatively impact consent decree operation share common facility manufacturing operation certain cost associate party certification decrease completion work plan certify financial impact continue cost new process continue reduced product mix volume site company manufacture cost base relatively fix action management significantly reduce company manufacturing infrastructure involve complex issue case shift product manufacture plant year construction revalidation registration requirement management continue review carry value certain manufacturing asset indication impairment future event decision lead asset impairment andor relate cost company repatriate approximately billion previously unremitte foreign earning reduce tax rate provide american job creation act ajca repatriate fund ajca benefit company follow way company operation currently incur significant negative cash flow operating cash flow exist cash investment include repatriation ajca expect provide company ability fund cash need near intermediate term company continue use repatriated fund ajca qualified spend operation produce tax net operating loss nol carryforward approximately billion ajca qualifying repatriation reduce tax loss company cash necessary fund cash need potential benefit able carry forward nol reduce future taxable income potential future benefit significant dependent company achieve profitability discussion operating result net sale significant portion net sale major pharmaceutical health care product distributor major retail chain consequently net sale quarterly growth comparison affect fluctuation buy pattern major distributor retail chain trade buyer fluctuation result seasonality pricing wholesaler buying decision factor consolidate net sale total billion increase billion percent compare consolidated net sale reflect high volume remicade pegintron nasonex temodar inclusion year sale avelox cipro addition foreign exchange favorable impact percent consolidate net sale billion decrease million percent compare primarily reflect volume decline offset favorable foreign exchange rate impact percent table content net sale year end december follow incr ease decr ease ollar million prescription pharmaceutical remicade pegintron nasonex clarinex aerius temodar claritin rxa rebetol integrilin intron avelox subutex caelyx cipro elocon pharmaceutical consumer health care otcb foot care sun care animal health consolidate net sale certain prior year amount reclassify conform current year presentation meaningful percentage amount show include international sale claritin include otc claritin respectively international net sale remicade treatment immunemediate inflammatory disorder rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylose spondylitis plaque psoriasis million percent million great demand expand indication continue market growth sale remicade million million percent compare great medical use expand indication european market near future additional competitive product indication refer likely introduce global net sale pegintron powder injection pegylate interferon product treat hepatitis increase million percent million compare december launch pegintron rebetol combination therapy japan sales japan benefit significant number patient wait approval pegintron begin treatment patient warehousing comparison unfavorably impact absence patient warehousing anticipate government mandate price reduction japan result factor sale decline materially sale pegintron decrease primarily reflect decline overall market sale pegintron decrease table content million percent million primarily loss market share reflect entrance competitor new product hepatitis market global net sale nasonex nasal spray oncedaily corticosteroid nasal spray allergy rise percent million product capture great international market share versus period sale benefit increase promotional effort introduction begin january new scentfree alcoholfree formulation nasonex nasal spray sale nasonex increase percent versus million primarily international sale growth favorable prior year trade inventory comparison temper decline market share generic flonase fluticasone propionate approve unfavorably impact corticosteroid nasal spray market global net sale clarinex market aerius country outside treatment seasonal outdoor allergy yearround indoor allergy decrease million percent versus sale decrease million percent versus reduce market share decline market september generic allegra fexofenadine introduce continue negatively affect antihistamine market include clarinex sale outside increase million percent million primarily market share gain global net sale clarinex million essentially flat versus sale outside increase percent million market share gain continue conversion prescription claritin sale decrease percent million continue contraction prescription antihistamine market follow launch otc claritin brand nonbranded nonsedate antihistamine couple market share decline global net sale temodar capsule treatment certain type brain tumor increase million percent million increase utilization treat newly diagnose glioblastoma multiforme gbm prevalent form brain cancer new indication grant fda approval march rapidly adopt physicians june temodar receive approval european commission use combination radiotherapy gbm patient member state iceland norway japan temodar grant priority review regulatory application treat malignant glioma fourth quarter sale temodar increase million percent million increase market penetration growth rate temodar moderate go forward significant market penetration achieve treatment gbm especially international net sale prescription claritin increase million percent million launch claritin reditab japan couple unusually severe japanese allergy season recur international sale prescription claritin million decrease percent compare continue conversion clarinex global net sale rebetol capsule use combination intron pegintron treat hepatitis increase million percent million primarily launch pegintron rebetol combination therapy japan december sales japan benefit significant number patient wait approval pegintron begin treatment patient warehousing comparison unfavorably impact absence patient warehousing result sale decline materially rebetol subject large average government mandate price reduction japan sales rebetol decrease percent million launch generic version rebetol april increase price competition outside global net sale integrilin injection glycoprotein platelet aggregation inhibitor treatment patient acute coronary syndrome sell primarily company million compare million sale integrilin essentially flat versus sale outside decrease million reflect return table content european marketing right millennium pharmaceuticals inc millennium sale integrilin increase million percent versus increase patient utilization effective september company restructure integrilin copromotion agreement millennium term restructure agreement company acquire exclusive development commercialization right integrilin exchange upfront payment million royalty integrilin sale restructure agreement call minimum royalty payment million year millennium global net sale intron injection chronic hepatitis antiviral anticancer indication decrease percent million conversion pegintron japan sales intron decrease percent million primarily low demand net sale avelox fluoroquinolone antibiotic treatment certain respiratory skin infection sell primarily scheringplough result company license agreement bayer million sale avelox represent initial month sale agreement bayer effective october international net sale subutex tablet treatment opiate addiction increase percent million increase market penetration sale subutex million increase percent increase market penetration expect subutex encounter generic competition near future international sale caelyx treatment ovarian cancer metastatic breast cancer kaposis sarcoma increase percent million reflect adoption ovarian cancer metastatic breast cancer indication sale caelyx increase percent versus million reflect initial adoption metastatic breast cancer indication net sale cipro fluoroquinolone antibiotic treatment certain respiratory skin urinary tract infection sell primarily scheringplough result company license agreement bayer million sale cipro represent initial month sale agreement bayer global net sale elocon cream mediumpotency topical steroid decrease percent million reflect generic competition introduce quarter generic competition expect continue adversely affect sale product pharmaceutical net sale include large number low sale volume prescription pharmaceutical product product sell limited market outside multiple source product long protect patent product include treatment respiratory cardiovascular dermatological infectious oncological disease global net sale consumer health care product include otc foot care sun care product billion sale otc claritin million decrease million percent reflect adverse impact sale claritind restriction retail sale otc product contain pseudoephedrine pse come effect sale claritind continue adversely affect recent future restriction retail sale product addition otc claritin continue face competition private label brand loratadine net sale sun care product increase million percent primarily launch new coppertone continuous spray product couple strong overall suncare season net sale foot care product increase million percent primarily new memory fit insole insole product net sale consumer health care product increase million percent compare primarily strong performance scholl freeze away foot care product table content company sell numerous nonprescription upper respiratory product contain pse fdaapprove ingredient relief nasal congestion company annual north american sale nonprescription upper respiratory product contain pse total approximately million million approximately million product include claritind product drixoral coricidin chlortrimeton product company understand pse illicit manufacture methamphetamine dangerous addictive drug december states canada mexico enact regulation concern nonprescription sale product contain pse include limit product purchase time require product locate pharmacist counter state goal deter illicitillegal manufacture methamphetamine additional state enact limit quantity pse person possess state recently enact legislation regulate pse product prescription status federal government propose legislation place restriction sale product contain pse major retailer customer company voluntarily place nonprescription product contain pse pharmacy counter store require local law sale nonprescription pse product million approximately percent compare company continue monitor development area negative impact operation financial result note regulation relate sale prescription product clarinexd product contain pse global net sale animal health product increase percent million increase sale reflect strong growth core brand geographic specie area lead product serve cattle market include nuflor vaccine business increase sale well product supply sale growth include favorable foreign exchange impact percent company expect growth rate moderate increase competition include generic product global net sale animal health product increase percent include favorable foreign exchange impact percent certain situation positive impact sale net income recur include favorable effect foreign exchange patient warehousing benefit pegintron rebetol relate launch pegintron japan unusually severe allergy season japan benefit report sale prescription claritin generic allegra fexofenadine introduce expect negative impact clarinex sales generic flonase fluticasone propionate approve unfavorably impact corticosteroid nasal spray market growth remicade affect increase competition addition company expect growth rate animal health business moderate increase competition include generic product table content cost expense equity income summary cost expense equity income year end december follow incr ease dec rease ollar million cost sale sell general administrative sga research development expenseincome net special charge equity income cholesterol joint venture meaningful percentage substantially sale cholesterol product include company net sale result sale reflect equity income cholesterol joint venture addition virtual nature joint venture company incur substantial sell general administrative expense capture equity income include company statement consolidated operation result company gross margin ratio sga expense expense percentage net sale reflect impact joint venture operate result gross margin gross margin increase compare percent percent primarily supply chain process improvement increase sale highermargin product favorable impact foreign exchange partly offset high royalty relate bayer product begin september royalty integrilin restructuring integrilin agreement substantially offset effect generally increase cost sale increase royalty offset reduced sell general administrative expense gross margin unfavorably impact year increase royalty restructure agreement gross margin decrease compare percent percent primarily low production volume couple increase spending relate fda consent decree manufacturing compliance spending effort upgrade company global infrastructure absence european losec revenues change product sale mix include sale bayer license product contribute unfavorable comparison sell general administrative selling general administrative expense sga increase percent billion versus billion increase primarily addition fourth quarter bayer sale representative increase selling expense europe support continue launch vytorin zetia increase promotional spending primarily nasonex asmanex product agreement bayer sga expense increase percent billion billion primarily expansion sale field force higher employeerelate cost unfavorable impact foreign exchange partially offset low promotional spending research development research development spending increase percent billion represent percent net sale include million charge conjunction company exercise right develop commercialize golimumab spending include million charge conjunction license toyama chemical company ltd garenoxacin generally change spending reflect timing company fund internal research table content effort research collaboration partner discover develop steady flow innovative product company believe strong early development pipeline widerange therapeutic area preclinical phase compound additionally later phase growthdriver pipeline enter phase iii thrombin receptor antagonist vicriviroc hcv protease inhibitor company anticipate approximate double annual patient enrollment clinical trial year versus level company expect spending increase compare prior year progression company earlystage pipeline increase clinical trial activity maximize company chance successful development new product company begin development excellence initiative build talent critical mass create uniform level excellence deliver highpriority program expenseincome net expenseincome net million lower reflect high net interest income high interest rate cash equivalent shortterm investment increase expenseincome net versus primarily result high net interest expense debt issuance special charge component special charge follow dollar million litigation charge employee termination cost asset impairment charge litigation charge litigation reserve increase million increase result total reserve million massachusetts investigation investigation disclose awp investigation state litigation disclose awp litigation note legal environmental regulatory matter represent company current estimate resolve matter additional information litigation reserve include note legal environmental regulatory matter item financial statement supplementary datum litigation reserve increase million primarily result investigation companys sale marketing practice employee termination cost august company announce global workforce reduction initiative phase initiative voluntary early retirement program verp program eligible employee december elect early retirement receive enhance retirement benefit approximately employee elect retire program retire december total cost program approximately million comprise increase pension cost million increase postretirement health care cost million vacation payment million cost relate accelerate vest stock grant table content million amount recognize program million million million respectively additional amount expect recognize program termination cost associate verp total million million million respectively follow summarize activity account related employee termination cost emplo yee termination cost dollar million special charge incur credit retirement benefit plan liability disbursement special charge liability balance december special charge incur credit retirement benefit plan liability disbursement special charge liability balance december special charge incur credit retirement benefit plan liability disbursement special charge liability balance december asset impairment charge year end december company recognize asset impairment charge million relate primarily consolidation company biotechnology organization company record asset impairment charge million relate primarily shutdown small european research development facility asset impairment charge million relate closure manufacturing facility united kingdom writedown production equipment relate product long go produce manufacturing site operate fda consent decree write drug license sun care trade expect cash flow support carry value equity income cholesterol joint venture global cholesterol franchise sale include sale company cholesterol joint venture merck vytorin zetia total billion billion million respectively sale comparison benefit launch vytorin second half franchise product combine pass percent share level new prescription cholesterol management market base january ims data vytorin launch country include august zetia approve country launch country company utilize equity method account joint venture sharing income operation base percentage vary product sale level country company allocation joint venture income increase milestone earn merck scheringplough partner bear cost general sale force commercial overhead marketing joint venture product world canada puerto rico joint venture reimburse partner predefine physician detail set annual basis company table content report reimbursement equity income cholesterol joint venture reimbursement represent reimbursement specific incremental identifiable cost company detail cholesterol product market addition reimbursement reflective scheringplough sale effort relate joint venture scheringplough sale force relate cost associate joint venture generally estimate high cost joint venture partner contractually share portion manufacturing cost specifically identify promotion cost include directto consumer advertising direct identifiable outofpocket promotion agree cost specific service market support market research market expansion specialty sale force physician education program certain specify research development expense generally share equally partner equity income cholesterol joint venture total million million million respectively equity income comparison benefit launch vytorin second half company recognize milestone merck million million million respectively million milestone relate certain european approval vytorin ezetimibesimvastatin million milestone relate approval ezetimibesimvastatin mexico million milestone relate certain european approval zetia amount include equity income certain condition specify joint venture agreement merck company earn additional milestone total million noted company incur substantial sell general administrative cost reflect equity income cholesterol joint venture instead include overall cost structure company provision income taxis tax expense million million million respectively overall income tax expense net benefit describe primarily relate foreign taxis include benefit relate net operating loss nol company establish valuation allowance net defer tax asset include benefit nols management conclude likely benefit net defer tax asset realize december company nol carryforward total approximately billion company tax provision year end december include federal income tax benefit approximately million result irs notice issue august provision notice result reduction previously accrue tax liability attributable ajca repatriation reduce nol carry forward subsequent year income tax provision include charge approximately million relate foreign taxis million state taxis benefit million federal taxis primarily related irs notice mention january internal revenue service irs complete examination company federal income tax return company cash payment quarter form tax deposit approximately million anticipation settlement tax examination prevent additional irs interest charge payment fully satisfied liability associate tax examination consistent previously record reserve irs currently examine company federal income tax return table content net incomeloss available common shareholder net income available common shareholder include deduction prefer stock dividend million relate issuance percent mandatory convertible preferred stock august net loss available common shareholder include deduction prefer stock dividend million liquidity financial resource discussion cash flow ar nde december dollar million cash flow operating activity cash flow investing activity cash flow financing activity cash flow operating activity worldwide basis approximate cash payment capital expenditure dividend international operation generate cash excess local cash need operation cash need excess cash generate operation fund dividend payment majority research development cost capital expenditure year prior overall cash need fund primarily operation cash requirement include operate cash need capital expenditure tax payment dividend common preferred share approximate billion consolidated operating activity generate million cash compare use million increase primarily high net income timing payment special charge relate litigation partially offset increase account receivable sale growth payment tax authority tax liability relate repatriation foreign earning ajca approximately million tax deposit million anticipate settlement certain tax contingency tax year tax charge relate ajca expense operate cash flow favorably impact tax refund million result loss carry cash flow unfavorably impact million payment government tax deficiency relate certain transaction tax year payment million settlement agreement attorney office eastern district pennsylvania operating activity provide approximately million cash include cash flow benefit reduction account receivable follow end sale claritin prescription product include million payment term fda consent decree net cash investing activity million primarily relate million capital expenditure purchase intangible asset million partially offset proceed sale property equipment million net reduction shortterm investment million net cash investing activity million include capital expenditure million net purchase investment million partially offset cash proceed million transfer license right million disposition property equipment net cash financing activity million compare net cash provide financing activity billion use cash financing activity include table content payment dividend common prefer share million repayment billion commercial paper borrowing partially offset proceed million bank debt incur foreign subsidiary relate funding portion repatriation ajca net cash provide financing activity reflect proceed billion preferred stock issuance million increase shortterm borrowing partially offset payment dividend common prefer share million company financial situation begin improve company move forward additional investment enhance infrastructure business includes expect capital expenditure million year pharmaceutical sciences center center allow company streamline integrate company drug development process product move drug discovery pipeline market additional related expenditure upgrade equipment staffing center operation continue generate negative cash flow payment litigation investigation increase cash need operate cash flow exist cash investment include repatriation ajca expect provide company ability fund cash need include cash need near intermediate term total cash cash equivalent shortterm investment total debt approximately billion december august company issue percent mandatory convertible preferred stock note shareholder equity item financial statement supplementary datum receive net proceed billion deducting commission discount underwriting expense proceed reduce shortterm commercial paper borrowing pay tax litigation settlement amount litigation cost fund operating expense shareholder dividend capital expenditure prefer stock issue company billion shelf registration december million remain register unissue shelf registration borrowing credit facility november company issue billion aggregate principal percent senior unsecured note billion aggregate principal percent senior unsecured note proceed offer billion general corporate purpose include repay commercial paper outstanding issuance note rate moodys investor service moodys credit watch negative implication standard poor interest rate payable note subject adjustment rating assign note moodys downgrade respectively interest rate payable series note increase note shortterm borrowing longterm debt commitment item financial statement supplementary datum additional information july moodys lower rating note baa accordingly interest payable note increase basis point effective december december interest rate payable note increase percent percent interest rate payable note increase percent percent adjustment interest rate payable note increase company interest expense approximately million annually company revolve credit facility syndicate major financial institution march company negotiate increase bank commitment billion billion change basic term preexist credit facility concurrently increase commitment facility company terminate early separate million line credit mature outstanding balance facility time terminate table content exist billion credit facility mature require company maintain total debt total capital ratio percent credit line available general corporate purpose consider support company commercial paper borrowing borrowing credit facility draw parent company whollyowne international subsidiary accompany parent guarantee facility require compensating balance nominal commitment fee pay december million draw facility wholly own international subsidiary purpose funding ajca relate repatriation addition aforementioned credit facility company enter million credit facility fourth quarter draw december credit facility utilize whollyowne international subsidiary fund repatriation ajca credit facility require company maintain total debt total capital ratio percent borrowing payable later november fund borrow facility subsequently repay reborrowe credit facility borrowing classify shortterm borrowing company intend repay amount month december shortterm borrowing include credit facility mention total billion billion respectively commercial paper outstanding december million billion respectively weightedaverage interest rate shortterm borrowing december percent percent respectively credit rating company current unsecured senior credit rating outlook follow senior unsecured credit rating long term sho rtterm tlook moodys investor service baa egative standard poor negative fitch rating negative commercial paper rating discuss significantly affect company ability issue rollover outstanding commercial paper borrowing time company believe ability commercial paper issuer company shortterm credit rating moodys andor fitch issue rollover outstanding commercial paper time company high shortterm credit rating addition total commercial paper capacity available issuer typically higherrate company company maintain sizable line credit commercial bank cash shortterm investment hold international subsidiary serve alternative source liquidity support commercial paper program company credit rating decline current level impact decline reduce availability commercial paper borrowing increase interest rate company short longterm debt discuss company believe exist cash balance cash generate operation allow company fund cash need near intermediate term table content contractual obligation payment period company know contractual obligation december follow payman iod total year year year year dolla million shortterm borrowing current portion longterm debt longterm debt obligation operating lease obligation purchase obligation advertising contract research contract capital expenditure commitment purchase obligation obligation total longterm debt obligation include million aggregate principal percent senior unsecured note million aggregate principal percent senior unsecured note exclude interest obligation note shortterm borrowing longterm debt commitment item financial statement supplementary datum additional information research contract include potential milestone payment payment contingent occurrence certain event table exclude research contract cancelable company penalty purchase obligation consist cancelable noncancelable inventory expense item caption include obligation base undiscounted amount estimate payment certain company pension defer compensation plan prefer stock dividend contractual obligation regulatory competitive environment company operate company subject jurisdiction national state local regulatory agency regulation describe detail item business regulatory compliance complex regulatory standard include good clinical practice good laboratory practice good manufacturing practice vary jurisdiction constantly evolve regulatory compliance costly regulatory compliance impact timing need bring new drug market market drug new indication failure comply regulation result delay approval drug seizure recall drug suspension revocation authority necessary production sale drug fine civil criminal sanction regulatory compliance cost compliance failure material impact company result operation cash flow financial condition company work fda consent decree resolve issue involve company compliance current good manufacturing practice cgmp certain table content manufacturing site new jersey puerto rico detail note consent decree item financial statement supplementary datum term consent decree company payment total million end company complete revalidation program bulk active pharmaceutical ingredient finish drug product significant step cgmp work plan accordance schedule require consent decree company completion cgmp work plan currently pende certification party expert certification turn subject acceptance fda term decree provide fda notify company significant violation fda law regulation decree year period decree entry company petition court decree dissolve fda oppose company petition company subject pharmacovigilance reporting requirement country jurisdiction include european union member states requirement differ jurisdiction jurisdiction include requirement report adverse event occur patient particular drug order alert manufacturer drug governmental agency potential problem pharmacovigilance inspection official british french medicine agency conduct request european agency evaluation medicinal product emea cite deficiency report process company continue work longterm action plan rectify deficiency provide regular update emea fourth quarter local emea regulatory authority conduct follow inspection assess company implementation action plan inspector acknowledge progress continue note significant concern quality system support company pharmacovigilance process similarly follow inspection company clinical trial practice inspector identify issue respect company management clinical trial relate pharmacovigilance practice company intend continue upgrade skill process system clinical practice pharmacovigilance company remain committed accomplish work invest significant resource area february company announce initiative build clinical excellence trial design execution tracking strengthen company scientific compliance rigor global basis company know action emea national authority response inspection possible action include inspection demand improvement report system criminal sanction company andor responsible individual change condition marketing authorization company product recently clinical trial postmarkete surveillance certain market drug competitor industry raise safety concern lead recall withdrawal adverse labeling market product addition situation raise concern prescriber patient relate safety efficacy pharmaceutical product general company personnel regular open dialogue fda regulator review product label material regular basis new information know follow wake recent product withdrawal company significant safety issue health authority fda emea pmda increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication rereviewe select product market add uncertainty regulatory process great regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising table content similarly major health authority include fda emea pmda increase collaboration especially regard evaluation safety benefitrisk information medium attention increase current environment health authority regulatory action market safety labeling change regulatory prescribing marketing implication market extent previously see health authority pmda japan publicly acknowledge significant backlog workload resource constraint agency backlog cause long regulatory review time new indication product include initial approval zetia japan add uncertainty predict approval timeline market pmda committed correct backlog expect continue foreseeable future fda issue final rule remove essential use designation albuterol cfc product removal designation require cfc albuterol product include company proventil cfc remove market later december necessitate transition marketplace albuterol cfc proventil albuterol hfa proventil hfa later end difficult predict impact transition albuterol marketplace company product uncertaintie inherent government regulatory approval process include thing delay approval new product formulation indication affect company operation effect regulatory approval process operation predict company achieve significant number important regulatory approval include approval vytorin clarinex clarinex reditab clarinex new indication temodar nasonex significant approval include asmanex dpi dry powder inhalation united states noxafil pegintron japan new indication remicade company number significant regulatory submission file major market await approval describe specifically note legal environmental regulatory matter item financial statement supplementary datum pricing sale marketing program arrangement relate business practice company participant health care industry increase scrutiny federal state regulatory investigative prosecutorial administrative entity entity include department justice attorney office office inspector general department health human service fda federal trade commission ftc state attorney general office health care law certain governmental entity operate include federal state antikickback statute statutory common law false claim law construe broadly court permit government entity exercise significant discretion event governmental entity believe wrongdoing occur institute civil criminal proceeding institute resolve unfavorably subject company substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program company predict investigation affect marketing practice sale result material adverse impact company result operation cash flow financial condition business company pharmaceutical product subject increasingly competitive pricing manage care group institution government agency group seek price discount market company pharmaceutical manufacturer require provide statutorily define rebate government agency order participate medicaid veterans health care program governmentfunde program international market company operate environment government mandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug enact acrosstheboard price table content cut method control cost example japan generally enact biennial price reduction expect occur pricing action occur certain major european market company unable predict final form time future domestic international governmental health care initiative include passage law permit importation pharmaceutical effect operation cash flow reasonably estimate similarly effect operation cash flow decision government entity manage care group group concern formulary pharmaceutical reimbursement policy reasonably estimate company predict net effect medicare prescription drug benefit market sale new medicare drug benefit medicare take effect january offer voluntary prescription drug coverage subsidize medicare million medicare beneficiary compete private prescription drug plan pdps medicare advantage plan company lead drug cover medicare temodar integrilin intron medicare provide payment physician service include prescription drug administer physician service manner drug reimburse medicare limit companys ability offer large price concession large price increase drug scheringplough drug relatively small portion sale medicare population clarinex hepatitis franchise company experience expand utilization vytorin zetia new drug company pipeline great consequence company legislation impact pricing rebate discount market pharmaceutical product competitive company operation affect technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor new information clinical trial market product postmarkete surveillance generic competition company product mature addition patent position increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product effect operation competitive factor patent dispute predict outlook relate financial performance company anticipate sale profit pivotal cholesterol franchise continue grow company gross margin improve result thing operate efficiency plant reduce spend relate consent decree improvement gross margin expect moderate improvement offset royalty payment partner company anticipate expense grow fast rate net sale depend time study success phase trial underway thrombin receptor antagonist hepatitis protease inhibitor hiv drug vicriviroc company move forward action agenda additional investment anticipate enhance infrastructure area clinical development pharmacovigilance information technology risk describe item risk factor cause actual result differ expectation provide section impact recently issue accounting standard november fasb issue statement financial accounting standard sfas inventory cost sfas require abnormal spoilage expense period incur table content oppose inventoried amortize income inventory usage fix production facility overhead cost allocate normal production level facility company implement sfas fourth quarter implementation sfas material impact company financial statement march fasb issue interpretation fin sfas accounting conditional asset retirement obligation clarify term conditional asset retirement obligation sfas term refer legal obligation perform asset retirement activity time andor method settlement conditional future event control entity accordingly company require recognize liability fair value conditional asset retirement obligation fair value liability reasonably estimate interpretation effective later end fiscal year end december retroactive application require company implement fin fourth quarter implementation fin material impact company financial statement december fasb issue sfas revise sharebased payment sfas sfas effective company january sfas require company recognize compensation cost relate sharebased transaction compensation base market performance company share fair value basis company adopt sfas quarter modify prospective method modify prospective method require company recognize compensation cost sharebase grant january unrecognized cost unvested award date adoption adoption sfas company recognize sharebased compensation cost service period early employee retirement eligibility date state vest period award grant issue retirement eligible employee prior adoption sfas company recognize compensation cost state vest period acceleration unrecognize compensation cost retirement employee sfas amend sfas statement cash flow require excess tax benefit reflect operate cash flow reflect finance cash flow note summary significant accounting policy item financial statement supplementary datum present pro forma disclosure reflect effect net incomeloss stock base compensation apply sfas accounting stockbase compensation fair value method result adoption sfas companys compensation expense stock option defer stock unit expect consistent pro forma amount lower base timing number individual grant companys stock price assumption necessary estimate fair value addition company compensation plan account sfas liabilitybase plan ultimate cash payout liabilitybase plan base company stock price performance compare stock price performance peer group change accounting require sfas result cumulative effect million income january order recognize difference company previously accrue liability report accounting principle board apb opinion number fair value liability plan future operating result impact fluctuation fair value liability plan require remeasure reporting date critical accounting policy follow accounting policy consider significant change certain judgment assumption inherent policy affect company financial statement revenue recognition rebate discount return provision income taxis table content impairment intangible asset property accounting pension postretirement benefit plan account legal regulatory matter revenue recognition company pharmaceutical product sell direct purchaser wholesaler retailer certain health maintenance organization price discount rebate sale pay federal state agency indirect purchaser market participant manage care organization indemnify beneficiary health plan pharmaceutical cost pharmacy benefit manager company recognize revenue title risk loss pass purchaser reliable estimate follow determined commercial discount rebate arrangements rebate obligation certain federal state governmental program iii sale return normal course business recognize revenue company estimate record applicable commercial governmental discount rebate sale return expect grant product sell period amount deduct sale period estimate record prior period reevaluate process reliable estimate item company defer recognition revenue revenue recognition new product base specific fact circumstance include estimate acceptance rate establish product similar marketing characteristic absent ability reliable estimate rebate discount return company defer revenue recognition product discount grant base term arrangement wholesaler managedcare organization government purchaser market condition include price charge competitor rebate estimate base sale term historical experience trend analysis project market condition market serve company evaluate market condition product group product primarily analysis party demand market research datum internally generate information datum information provide purchaser obtain party subject inherent limitation accuracy validity sale return generally estimate record base historical sale return information analysis recent wholesale purchase information consideration stocking level wholesaler forecast demand amount product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze formulation return reserve company enter agreement major pharmaceutical wholesaler agreement deal number commercial issue product return time payment processing chargeback quantity inventory hold wholesaler respect quantity inventory hold wholesaler agreement provide financial disincentive wholesaler acquire quantity product excess necessary meet current patient demand use monitoring note agreement company expect avoid situation company shipment product reflective current demand rebate discount return rebate accrual federal state governmental program million december million december commercial discount rebate accrual table content million december million december rebate accrual establish period relate revenue recognize result reduction sale establishment liability include total current liability case governmental rebate program company payment involve interpretation relevant statute regulation interpretation subject challenge change interpretive guidance governmental authority result challenge change affect estimate governmental rebate amount ultimately sufficient satisfy company obligation additional information governmental inquiry focus calculation rebate contain note legal environmental regulatory matter item financial statement supplementary datum addition possible result governmental challenge change interpretive guidance actual rebate materially exceed amount accrue follow summarize activity account relate accrued rebate sale return discount year nde year nde december december dollar illion accrue rebate return discount begin period provision rebate payment provision return return provision discount discount grant accrue rebate return discount end period management make estimate use assumption record accrual actual amount pay current period consistent previously estimate certain prior year amount conform reflect current year presentation provision income taxis december taxis provide approximately billion undistributed earning international subsidiary company consider earning permanently reinveste international subsidiary companys potential tax exposure result vary application statute regulation interpretation include exposure intercompany term cross border arrangement utilization cash hold foreign subsidiary investment property company cross border arrangement affiliate base internationally accept standard tax authority jurisdiction disagree subsequently challenge profit tax country reasonably possible ultimate resolution tax matter materially affect shareholder equity liquidity andor cash flow company believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority company accrue liability identify tax contingency result tax position take challenge tax authority company believe tax reserve reflect probable table content outcome identify tax contingency reasonably possible ultimate resolution tax matter materially great accrue company record valuation allowance reduce defer tax asset likely realize company consider ongoing prudent feasible tax planning strategy assess need valuation allowance event company determine able realize additional portion net defer tax asset adjustment valuation allowance increase income period determination likewise company subsequently determine able realize additional portion remain net defer tax asset future adjustment defer tax asset charge income period determination impairment intangible asset property intangible asset represent capitalize cost purchase goodwill patent license form intellectual property total million december annual amortization expense year estimate approximately million year base intangible asset record december value asset subject continue scientific medical marketplace uncertainty example market pharmaceutical product withdraw market safety reason marketing product occur pronounce warning amount capitalize product need reduce impairment event give rise impairment inherent risk pharmaceutical industry predict management regularly review intangible asset possible impairment company manufacture site operate capacity overall cost operate manufacturing site significantly increase consent decree compliance activity company manufacture cost base relatively fix action management significantly reduce company manufacturing infrastructure involve complex issue case shift product manufacture plant year construction revalidation registration requirement management continue review carry value certain manufacturing asset indication impairment future event decision lead asset impairment andor relate cost account pension postretirement benefit plan pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption company assess pension postretirement benefit plan assumption regular basis evaluate assumption company consider factor include evaluation discount rate expect rate return plan asset healthcare cost trend rate retirement age assumption company historical assumption compare actual result analysis current market condition asset allocation note retirement plan postretirement benefit item financial statement supplementary datum additional information discount rate pension postretirement benefit plan calculation evaluate annually modify reflect prevail market rate measurement date highquality fix income debt instrument portfolio provide future cash flow need pay benefit include benefit obligation come country debt instrument thinly trade estimate base available market rate actuarial assumption base management good estimate judgment increase basis point discount rate assumption assumption hold constant estimate million favorable impact net pension postretirement benefit cost increase basis point expect rate return assumption assumption hold constant estimate million favorable impact net pension post retirement benefit cost table content expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company determine expect return major asset class principally equities fix income real estate return expectation asset class base assumption economic growth inflation support long term historical datum company actual experience return plan asset expect portfolio performance reflect contribution active management appropriate unrecognized net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption expect return base primarily calculate marketrelated value asset methodology asset gainslosse result actual return differ company expect return majority asset realize marketrelated value asset ratably fiveyear period total unrecognized net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee target investment portfolio company pension plan allocate percent equity percent fix income investment percent real estate target investment portfolio company postretirement benefit plan allocate percent equity percent fix income investment portfolio equity weighting consistent longterm nature plan benefit obligation nonus pension plan target investment portfolio varies base duration pension liability local governmental rule regulation substantially investment equities fix income value base quote public market value investment real estate value base periodic appraisal account legal regulatory matter management judgment estimate require account legal regulatory matter ongoing basis include insurance coverage company review status claim investigation legal proceeding ongoing basis time time company settle resolve matter term condition management believe good interest company resolution claim investigation legal proceeding individually aggregate material adverse effect company result operation cash flow financial condition market risk disclosure company expose market risk primarily change foreign currency exchange rate less extent interest rate equity price follow describe nature risk foreign currency exchange risk company subsidiary country sale outside account approximately percent global sale virtually sale denominate currency local country company report profit cash flow expose change exchange rate date management deem cost effective engage formulabase program hedge profit cash flow international operation derivative financial instrument companys international subsidiary purchase significant quantity inventory payable dollar manage level inventory relate payable rate inventory turnover provide level protection adverse change exchange rate risk adverse exchange rate change mitigate fact company international operation widespread table content addition point time company international subsidiary hold financial asset liability denominate currency dollar financial asset liability consist primarily shortterm party intercompany receivables payable change exchange rate affect translate value financial asset liability gain loss arise translation affect net income occasion company derivative hedge specific shortterm risk situation involve foreign currency exposure derivative transaction material interest rate equity price risk financial asset expose change interest rate andor equity price primarily cash equivalent shortterm investment debt equity security hold nonqualified trust employee benefit asset total billion december cash equivalent shortterm investment percent decrease interest rate decrease interest income approximately million security hold nonqualified trust longterm nature liability trust asset fund company exposure market risk deem low financial obligation expose variability interest rate primarily shortterm borrowing company maintain investment portfolio excess borrowing accordingly company mitigate exposure change interest rate relate financial obligation company longterm debt outstanding percent decrease interest rate increase fair value debt approximately million company expect refund debt disclosure notice cautionary statement private security litigation reform act management discussion analysis financial condition result operation section report write report oral statement time time company contain forwardlooke statement mean private security litigation reform act forwardlooke statement relate strictly historical current fact base current expectation forecast future event identify forwardlooke statement use word anticipate believe estimate expect forecast project intend plan potential similar word term particular forwardlooke statement include statement relate future action ability access capital market prospective product product approval time condition regulatory approval patent intellectual property protection future performance result current anticipate product sale effort research development program estimate rebate discount return expense program reduce expense cost saving reduction work force outcome contingency litigation investigation growth strategy financial result forwardlooke statement publication turn wrong guarantee company financial operational performance performance company stock company assume obligation update forwardlooke statement factor cause actual result differ company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know possible predict identify factor refer item risk factor report incorporate reference identification important factor respect risk uncertainty item quantitative qualitative disclosure market risk market risk disclosure set forth item management discussion analysis financial condition result operation table content item financial statement supplementary datum index financial statement statement consolidated operation year end december statement consolidated cash flow year end december consolidated balance sheet december statement consolidated shareholder equity year end december note consolidated financial statement report independent register public accounting firm table content scheringplough corporation subsidiary statement consolidated operation ar ded december ount illion exc ept share figure net sale cost sale sell general administrative research development expenseincome net special charge equity income cholesterol joint venture incomeloss income taxis income tax expense net incomeloss prefer stock dividend net incomeloss available common shareholder dilute earningsloss common share basic earningsloss common share dividend common share accompany note integral consolidated financial statement table content scheringplough corporation subsidiary statement consolidated cash flow ars ded december amount million operating activity net incomeloss adjustment reconcile net incomeloss net cash provide byused operating activity payment tax authority tax refund loss carryback special charge depreciation amortization change asset liability account receivable inventory prepaid expense asset account payable liability income taxis payable net cash provide operating activity invest activity capital expenditure disposition property equipment proceed transfer license purchase investment reduction investment net net cash investing activity financing activity cash dividend pay common shareholder cash dividend pay prefer shareholder proceed prefer stock issuance net shortterm borrowing payment shortterm borrowing issuance longterm debt reduction longterm debt net net cash provide financing activity effect exchange rate cash cash equivalent net decrease increase cash cash equivalent cash cash equivalent begin year cash cash equivalent end year supplemental disclosure cash pay interest net amount capitalize cash pay refunded income taxis note accompany note integral consolidated financial statement table content scheringplough corporation subsidiary consolidate balance sheet decembe amount illion share figure asset current asset cash cash equivalent shortterm investment account receivable allowance inventory defer income taxis prepaid expense current asset total current asset property cost land building improvement equipment construction progress total accumulate depreciation property net goodwill intangible asset net asset total asset liability shareholder equity current liability account payable shortterm borrowing current portion longterm debt foreign state income taxis accrue compensation accrue liability total current liability longterm liability longterm debt defer income taxis longterm liability total longterm liability commitment contingent liability note shareholder equity mandatory convertible preferred share par value issue share face value common share authorize share par value issue paidin capital retain earning accumulate comprehensive income total treasury share cost total shareholder equity total liability shareholder equity accompany note integral consolidated financial statement table content scheringplough corporation subsidiary statement consolidated shareholder equity accu mulate mandatory total convertible compre share prefer common paidin retain treasury hensive holder share share capital earning share income equity amoun millio balance january comprehensive income net loss foreign currency translation minimum pension liability net tax unrealized gain investment available sale net tax total comprehensive loss cash dividend common share stock incentive plan balance december comprehensive income net loss foreign currency translation minimum pension liability net tax unrealized gain investment available sale net tax total comprehensive loss issuance preferred stock cash dividend common share dividend preferred share stock incentive plan balance december comprehensive income net income foreign currency translation minimum pension liability net tax total comprehensive income cash dividend common share dividend preferred share stock incentive plan balance december accompanying note integral consolidated financial statement table content note consolidated financial statement summary significant accounting policy overview scheringplough company discover develop manufacture market medical therapy treatment enhance human health company market lead consumer brand overthecounter otc foot care sun care market operate global animal health business principle consolidation consolidated financial statement include scheringplough corporation subsidiary company intercompany balance transaction eliminate certain prior year amount reclassify conform current year presentation use estimate preparation financial statement conformity generally accept accounting principle require management estimate use assumption affect certain report amount disclosure actual amount differ equity method accounting company account share activity merck scheringplough cholesterol joint venture partnership joint venture merck inc merck equity method accounting company significant influence joint venture operate financial policy accordingly company share earning joint venture include consolidated net incomeloss revenue sale vytorin zetia recognize joint venture title risk loss pass customer equity income joint venture exclude profit arise transaction company joint venture time underlying profit realize joint venture transaction party company merck note equity income cholesterol joint venture information joint venture cash cash equivalent cash cash equivalent include operate cash highly liquid investment original maturity month shortterm investment shortterm investment carry fair value classify available sale investment consist time deposit certificate deposit commercial paper maturity year inventory inventory value low cost market cost determine lastin firstout lifo method substantial portion inventory locate cost inventory determine firstin firstout method fifo depreciation property equipment depreciation provide estimate useful life property generally use straightline method table content note consolidated financial statement continue useful life property generally follow asset category year building build improvement equipment company review carry value property equipment indication impairment accordance statement financial accounting standard sfas accounting impairment disposal longlive asset depreciation expense million million million respectively foreign currency translation net asset company international subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation account include comprehensive income remain international subsidiary nonmonetary asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include income exchange gain loss arise translate intercompany balance longterm investment nature record foreign currency translation account transactional exchange gain loss include income revenue recognition company pharmaceutical product sell direct purchaser wholesaler retailer certain health maintenance organization price discount rebate sale pay federal state agency indirect purchaser market participant manage care organization indemnify beneficiary health plan pharmaceutical cost pharmacy benefit manager company recognize revenue title risk loss pass purchaser reliable estimate follow determined commercial discount rebate arrangements rebate obligation certain federal state governmental program iii sale return normal course business recognize revenue company estimate record applicable commercial governmental discount rebate sale return expect grant product sell period amount deduct sale period estimate record prior period reevaluate process reliable estimate item company defer recognition revenue earning common share dilute earning common share compute dividing income available common shareholder sum weight average number common share outstanding plus dilutive effect share issuable defer stock unit exercise stock option impact table content note consolidated financial statement continue conversion mandatory convertible preferred share exclude calculation include security earning share calculation antidilutive diluted loss common share exclude effect share issuable defer stock unit exercise stock option impact conversion mandatory convertible preferred share include security earning share calculation antidilutive result low loss share diluted loss common share exclude effect share issuable defer stock unit exercise stock option include security antidilutive period present basic earningsloss common share compute dividing incomeloss available common shareholder weight average number common share outstanding goodwill intangible asset sfas goodwill intangible asset require intangible asset acquire individually group asset initially recognize measure base fair value intangible finite life amortize useful life intangible indefinite life include goodwill amortize company evaluate goodwill impairment fairvaluebased test goodwill determine impaired write estimate fair value company goodwill primarily related animal health business income taxis defer income taxis recognize future tax effect temporary difference financial income tax reporting basis company asset liability base enact tax law rate account stockbase compensation december company account stockbase compensation arrangement intrinsic value method stockbase employee compensation cost reflect net incomeloss company defer stock unit performance plan stock option grant plan exercise price equal market value underlie common stock date grant december fasb issue sfas revise sharebased payment sfas sfas effective company january sfas require company recognize compensation cost relate sharebased transaction compensation base market performance company share determine fair value basis company adopt sfas quarter modify prospective method modify prospective method require company recognize compensation cost sharebase grant january unrecognized cost unvested award date adoption adoption sfas company recognize sharebased compensation cost service period early employee retirement eligibility date state vest period award grant issue retirement eligible employee prior adoption sfas company recognize compensation cost state vest period acceleration unrecognize compensation cost retirement employee sfas amend sfas statement cash flow require excess tax benefit reflect operate cash flow reflect finance cash flow table content note consolidated financial statement continue addition company compensation plan account sfas liabilitybase plan ultimate cash payout liabilitybase plan base company stock price performance compare stock price performance peer group change accounting require sfas result cumulative effect million income january order recognize difference company previously accrue liability report accounting principle board apb opinion number accounting stock issue employee fair value liability plan future operating result impact fluctuation fair value liability plan require remeasure reporting date follow table reconcile net incomeloss available common shareholder basicdilute earningsloss common share report pro forma net incomeloss available common shareholder basicdilute earningsloss common share company expense grantdate fair value stock option defer stock unit permit sfas accounting stockbase compensation dollar million share datum net incomeloss available common shareholder report add expense include report net income defer stock unit net tax deduct pro forma expense stock option defer stock unit charge net incomeloss available common shareholder accordance sfas net tax pro forma net incomeloss available common shareholder fair value method dilute earningsloss common share dilute earningsloss common share report pro forma dilute earningsloss common share fair value method basic earningsloss common share basic earningsloss common share report pro forma basic earningsloss common share fair value method weightedaverage fair value option grant respectively fair value estimate blackschole optionprice model base follow assumption dividend yield volatility riskfree interest rate expect term option year impact recently issue accounting pronouncement november fasb issue sfas inventory cost sfas require abnormal spoilage expense period incur oppose inventoried amortize income table content note consolidated financial statement continue inventory usage fix production facility overhead cost allocate normal production level facility company implement sfas fourth quarter implementation sfas material impact company financial statement march fasb issue interpretation fin sfas accounting conditional asset retirement obligation clarify term conditional asset retirement obligation sfas term refer legal obligation perform asset retirement activity time andor method settlement conditional future event control entity accordingly company require recognize liability fair value conditional asset retirement obligation fair value liability reasonably estimate interpretation effective later end fiscal year end december retroactive application require company implement fin fourth quarter implementation fin material impact company financial statement special charge component special charge year end december follow dollar million litigation charge employee termination cost asset impairment relate charge litigation charge litigation reserve increase million result total reserve million massachusetts investigation investigation disclose awp investigation state litigation disclose awp litigation note legal environmental regulatory matter litigation reserve increase million primarily result investigation companys sale marketing practice note legal environmental regulatory matter additional information employee termination cost august company announce global workforce reduction initiative phase initiative voluntary early retirement program verp program eligible employee december elect early retirement receive enhance retirement benefit approximately employee elect retire program retire december total cost program approximately million comprise increase pension cost million increase postretirement health care cost million vacation payment million cost relate accelerate vest stock grant million amount recognize relate program year end december million million million respectively employee termination cost associate verp total million million million respectively table content note consolidated financial statement continue follow summarize activity account related employee termination cost employ termination cost dol lars million special charge incur credit retirement benefit plan liability disbursement special charge liability balance december special charge incur credit retirement benefit plan liability disbursement special charge liability balance december special charge incur credit retirement benefit plan liability disbursement special charge liability balance december asset impairment charge asset impairment charge recognize accordance sfas goodwill intangible asset sfas accounting impairment disposal longlive asset year end december company recognize asset impairment charge million relate primarily consolidation company biotechnology organization year end december company recognize asset impairment charge million base discount cash flow charge million relate primarily shutdown small european research development facility year end december company recognize asset impairment charge relate follow asset impairment charge total million recognize base discount cash flow analysis relate facility equipment company manufacture site asset impairment charge million base discount cash flow recognize related intangible asset license cancer therapy drug sell country outside impairment charge million relate trade company highend sun care brand recognize base discount cash flow equity income cholesterol joint venture company merck inc merck enter separate set agreement jointly develop market certain product include cholesterollowere drug allergyasthma drug december cholesterol agreement expand include country world japan general company agree collaborative activity agreement operate virtual joint venture maximum degree possible rely respective infrastructure company agreement table content note consolidated financial statement continue generally provide equal sharing development cost copromotion approve product company cholesterol agreement provide company merck jointly develop ezetimibe market zetia asia ezetrol europe oncedaily monotherapy coadministration statin drug iii oncedaily fixedcombination tablet ezetimibe simvastatin zocor merck cholesterolmodifye medicine combination medication ezetimibesimvastatin market vytorin inegy international country zetia ezetrol ezetimibe vytorin inegy combination ezetimibesimvastatin approve use launch international market company utilize equity method accounting recording share activity merck scheringplough cholesterol joint venture company net sale include sale joint venture cholesterol joint venture agreement provide share operating income generate joint venture base percentage vary product sale level country market company receive great share profit million annual zetia sale million annual zetia sale merck scheringplough partner generally share profit equally scheringplough allocation joint venture income increase milestone recognize partner share joint venture income operation subject reduction partner fail perform specify minimum number physician detail particular country partner agree annually minimum number physician detail country partner bear cost general sale force commercial overhead marketing joint venture product world canada puerto rico cholesterol agreement provide reimbursement partner physician detail set annual basis reimburse equal partner physician detail multiply contractual fix fee scheringplough report reimbursement equity income cholesterol joint venture represent reimbursement specific incremental identifiable cost company detail cholesterol product market addition reimbursement reflective company sale effort relate joint venture company sale force relate cost associate joint venture generally estimate high year end december company recognize milestone million milestone relate certain european approval vytorin ezetimibesimvastatin company recognize milestone million relate approval ezetimibesimvastatin mexico company recognize milestone million relate certain european approval zetia certain condition specify joint venture agreement merck company earn additional milestone total million cost joint venture partner contractually share portion manufacturing cost specifically identify promotion cost include directto consumer advertising direct identifiable outofpocket promotion agree cost specific service market support market research market expansion specialty sale force physician education program certain specify research development expense generally share equally partner table content note consolidated financial statement continue follow information provide summary component company equity income cholesterol joint venture year end december dollar million scheringplough share net incomeloss include milestone respectively reimbursement scheringplough physician detail elimination intercompany profit net total equity income cholesterol joint venture equity income joint venture exclude profit arise transaction company joint venture time underlying profit realize joint venture transaction party company merck virtual nature cholesterol joint venture company incur substantial cost sell general administrative cost reflect equity income bear overall cost structure company cost report respective line item statement consolidated operation cholesterol agreement provide jointly own facility product result joint venture manufacture facility own company merck allergyasthma agreement provide joint development marketing partner oncedaily fixedcombination tablet contain claritin singulair singulair merck oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis january merck scheringplough respiratory joint venture report result phase iii clinical trial fixedcombination tablet contain claritin singulair phase iii study demonstrate sufficient add benefit treatment seasonal allergic rhinitis claritin singulair combination tablet approval country remain clinical development new phase iii clinical trial plan expenseincome net component expenseincome net follow ollar million interest cost incur capitalize construction interest expense interest income foreign exchange loss net total expenseincome net table content note consolidated financial statement continue income taxis component consolidate incomeloss income taxis year end december follow dollar millions united states foreign total incomeloss income taxis income cholesterol joint venture include table base jurisdiction income earn component income tax expense year end december follow fede ral sta fore ign tot ollar million current defer total current defer total current defer total company tax provision year end december include federal income tax benefit approximately million result irs notice issue august provision notice result reduction previously accrue tax liability attributable american job creation act ajca repatriation reduce net operating loss nol carry forward subsequent year fourth quarter company decision repatriate approximately billion provision ajca maximum foreign earning qualified reduced tax rate percent intend repatriation earning result federal tax liability approximately million state income tax liability approximately million record income tax expense company repatriate approximately billion accordance plan repatriation ajca company continue use repatriated fund qualified spending prior ajca company intent permanently reinv unremitted earning international subsidiary amount repatriate ajca company maintain intent permanently reinvest earning international subsidiary company provide defer taxis approximately billion undistributed foreign earning december determine tax liability arise earning remit practicable table content note consolidated financial statement continue liability depend number factor include earning distribute operation generate taxable profit loss fourth quarter change tax planning strategy trigger company intent repatriate earning ajca management long able conclude likely realize benefit net defer tax asset include benefit relate nol general company establish valuation allowance net defer tax asset december company continue maintain valuation allowance net defer tax asset december defer income taxis provide temporary difference financial reporting basis tax basis company asset liability company defer tax asset result principally record certain item currently deductible tax purpose net operating loss tax credit carryforward company defer tax liability principally result use accelerate depreciation tax purpose component company defer tax asset liability december follow dollar illion defer tax asset net operating loss nol tax credit carryforward postretirement employee benefit inventory relate sale return reserve litigation accrual total defer tax asset defer tax liability depreciation inventory valuation total defer tax liability defer tax valuation allowance net defer tax asset change valuation allowance primarily increase nol defer taxis net operating loss carryforward principally relate nol research development tax credit foreign tax credit federal alternative minimum tax amt credit carryforward december company approximately billion nol income tax purpose available offset future taxable income nol expire vary amount unused december company approximately million tax credit carryforward expire million foreign tax credit carryforward expire million amt tax credit carryforward indefinite life approximately million billion nol generate respectively eligible carryback benefit provision tax law accordance provision company able table content note consolidated financial statement continue recoup previous taxis pay resulted income tax benefit million million respectively difference income taxis base statutory tax rate company income tax expense year end december follow dollar million income tax expensebenefit statutory rate increasedecrease taxis result low rate jurisdiction net federal benefit tax repatriate foreign earning act net credit nol tax benefit record provision valuation allowance net defer tax asset nondeductible litigation reserve reserve tax litigation research tax credit state income tax permanent difference net income tax effective tax rate low tax rate jurisdiction net primarily attributable company manufacturing subsidiary puerto rico singapore ireland operate incentive tax grant begin expire overall income tax expense primarily relate foreign taxis include benefit relate nol net consolidated income tax paymentsrefund exclusive payment relate tax examination litigation discuss million million million respectively january internal revenue service irs complete examination company federal income tax return company cash payment quarter form tax deposit approximately million anticipation settlement tax examination prevent additional irs interest charge payment fully satisfied liability associate tax examination consistent previously record reserve irs currently examine company federal income tax return company potential tax exposure result vary application statute regulation interpretation include exposure intercompany term cross border arrangement utilization cash hold foreign subsidiary investment property company cross border arrangement affiliate base internationally accept standard tax authority jurisdiction disagree subsequently challenge profit tax country reasonably possible ultimate resolution tax matter materially affect shareholder equity liquidity andor cash flow company believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority company accrue liability identify tax contingency result tax position take challenge tax authority company believe tax reserve reflect table content note consolidated financial statement continue probable outcome identify tax contingency reasonably possible ultimate resolution tax matter materially great accrue october irs auditor assert interest rate swap company enter unrelated party recharacterize loan affiliate company result additional tax liability tax year september company payment irs million income tax million interest company file refund claim tax interest irs december follow irss denial company claim refund company file suit district court district new jersey refund tax interest refund litigation currently discovery phase company tax reserve adequate cover mention payment retirement plan postretirement benefit plan description company define benefit pension plan cover eligible employee certain foreign country plan benefit normal retirement primarily base participant average final earning year service social security income modify early retirement death disability benefit available plan benefit fully vest year service plan provide continue accrual credit service employee opt postpone retirement remain employ company reach normal retirement age nonus pension plan offer benefit competitive local market condition addition company provide postretirement medical life insurance benefit eligible retiree dependent postretirement benefit plan measurement date majority plan liability december net pension postretirement benefit cost total million compare million million actuarial assumption consolidated weight average assumption determine benefit obligation december pos retirement retirement plan benefit discount rate rate increase future compensation assumption develop benefit obligation yearend consolidated weight average assumption determine net benefit cost year end december pos treti rem ent retirement plan benefit discount rate longterm expect rate return plan asset rate increase future compensation table content note consolidated financial statement continue assumption determine net periodic benefit cost year establish end previous year assumption determine benefit obligation establish yearend net periodic benefit cost actuarial present value benefit obligation base actuarial assumption determine annually base evaluation longterm trend market condition impact cost provide retirement benefit longterm expect rate return plan asset derive return assumption determine major asset class equity fix income real estate proportional basis return expectation asset class base largely assumption economic growth inflation support longterm historical datum weight average assume healthcare cost trend rate postretirement measurement purpose percent trend percent percent increase assume healthcare cost trend rate increase combined postretirement service interest cost million post retirement benefit obligation million percent decrease assume health care cost trend rate decrease combined postretirement service interest cost million postretirement benefit obligation million average retirement age assume base annual rate retirement experienced company component net periodic benefit cost component net pension postretirement benefit expense follow treti rem ent retirement plan benefit ollar millio service cost interest cost expect return plan asset amortization net termination benefit curtailment settlement net pension postretirement benefit expense termination benefit curtailment settlement cost primarily relate matter discuss note special charge table content note consolidated financial statement continue benefit obligation fund status component change benefit obligation follow postretirement retirement plan benefit ollar illion benefit obligation begin year service cost interest cost participant contribution effect exchange rate change benefit pay acquisition plan transfer actuarial lossesgain include assumption change plan amendment termination benefit curtailment benefit obligation end year benefit obligation overfunde plan benefit obligation underfunde plan termination benefit curtailment cost primarily relate matter discuss note special charge component change plan asset follow ost retirement retirement plan benefit llar illion fair value plan asset primarily stock bond begin year actual gain loss plan asset contribution acquisition plan transfer effect exchange rate change benefit pay fair value plan asset end year plan asset overfunde plan plan asset underfunde plan addition plan asset indicate december security investment million million respectively hold nonqualified trust designate provide pension benefit certain underfunde plan december accumulate benefit obligation abo retirement plan million million respectively aggregate accumulate benefit obligation table content note consolidated financial statement continue fair value plan asset retirement plan accumulate benefit obligation excess plan asset million million respectively december million million respectively december accordance fasb staff position accounting disclosure requirement relate medicare prescription drug improvement modernization act medicare act company begin account effect federal subsidy medicare act quarter result company accumulate postretirement benefit obligation reduce million company net postretirement benefit expense reduce million reduction postretirement benefit expense consist reduction service cost interest cost net amortization million million million respectively follow reconciliation fund status plan net assetliability postretirement retirement plan benefit ollar illion benefit obligation excess plan asset post measurement date contribution unrecognize prior service cost unrecognize net actuarial loss net assetliability end year unrecognize actuarial gain loss primarily represent cumulative difference actuarial assumption actual return plan asset change discount rate plan experience december company unrecognize net actuarial loss million retirement plan million postretirement benefit plan total unrecognized net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee component net assetliability record consolidated balance sheet follow oth postretirement retirement plan benefit dollar millions prepaid benefit cost accrue benefit cost intangible asset accumulate comprehensive income net assetliability end year december company additional minimum pension liability million million respectively primarily relate domestic retirement plan result adjustment accumulate comprehensive incomeloss net tax million million respectively table content note consolidated financial statement continue plan asset fair value asset allocation consolidated retirement plan december target allocation follow rcen tage plan asset target december allocation asset category equity security debt security real estate total asset allocation postretirement benefit trust december target allocation follow rcen tage plan asset target december allocation asset category equity security debt security total company investment relate plan broadly diversify consist primarily equity fix income security objective generate longterm investment return consistent acceptable level overall portfolio market value risk asset periodically rebalance target allocation estimate future benefit payment follow benefit payment reflect expect future service appropriate expect pay retirement postretirement plan benefit dollar million year expect benefit payment reduce expect subsidy payment medicare act million million million million million million respectively company practice fund qualified pension plan sufficient amount meet minimum requirement set forth applicable law table content note consolidated financial statement continue company expect contribute approximately million retirement plan include million retirement plan contribution change base outcome pende funding reform legislation define contribution plan company define contribution profitshare plan cover substantially fulltime domestic employee complete year service annual contribution determine formula base company income shareholder equity participant compensation profit sharing contribution determine formula describe company long make contribution plan begin company make contribution exist define contribution saving plan equal percent eligible employee earning plus match percent eligible employee earning base employee contribution plan total company contribution plan million million respectively earning common share follow table reconcile component basic dilute earningsloss share computation dol lars sha res millio eps numerator net incomeloss prefer stock dividend net incomeloss available common shareholder eps denominator average share outstanding basic eps dilutive effect option defer stock unit average share outstanding diluted eps equivalent common share issuable company stock incentive plan exclude computation dilute eps effect antidilutive million million million respectively year end december respectively year end december million million common share respectively obtainable conversion company percent mandatory convertible preferred stock exclude computation dilute earning share effect antidilutive comprehensive incomeloss component accumulate comprehensive incomeloss december dollar illion foreign currency translation adjustment minimum pension liability net tax unrealized gain investment available sale net tax total table content note consolidated financial statement continue gross unrealized pretax gain investment million respectively unrealize loss immaterial inventory inventory consist follow december dollar illion finish product good process raw material supply total inventory inventory value lastin firstout basis comprise approximately percent total inventory december estimate replacement cost total inventory december million million respectively intangible asset component intangible asset net follow december gross gross carrying accumulate carry accumulate amortization net amortization net doll ar million patent license trademark total intangible asset include pension asset million million respectively patent license trademark amortize straightline method respective useful life residual value intangible asset estimate zero company record million base technology intangible relate acquisition neogenesis asset amortize year company restructure integrilin copromotion agreement millennium pharmaceuticals inc millennium result million include intangible asset amortize approximately year include intangible asset approximately million relate license copromotion agreement bayer amount amortize effective useful life agreement range seven year note product license acquisition additional information transaction net carrying patent license reduce approximately million result bristolmyer squibbs reacquisition promotion right tequin amortization expense relate intangible asset million million million respectively intangible asset review determine table content note consolidated financial statement continue recoverability compare carry value expect undiscounted future cash flow event circumstance warrant review product license acquisition february company acquire asset neogenesis pharmaceutical approximately million million record intangible asset relate base technology neogenesis apply novel screening chemistry technology discover new drug candidate august company announce exercise right develop commercialize centocor inc centocor golimumab fully human monoclonal antibody develop therapy treatment rheumatoid arthritis immunemediate inflammatory disease pursuant exercise company receive exclusive worldwide marketing right golimumab exclude japan china include hong kong taiwan indonesia exchange right agreement company upfront payment million centocor tax benefit million payment expense report research development year end december statement consolidated operation company share development cost centocor effective september company restructure integrilin copromotion agreement millennium term restructure agreement company acquire exclusive development commercialization right integrilin exchange upfront payment million royalty integrilin sale company agree pay minimum royalty million year millennium company purchase exist integrilin inventory millennium million upfront payment capitalize include intangible asset company enter collaboration license agreement toyama chemical ltd toyama term agreement company acquire exclusive worldwide right exclude japan korea china develop use sell garenoxacin human veterinary use exclude topical ophthalmic application garenoxacin toyamas quinolone antibacterial agent currently regulatory review connection execution agreement company incur charge second quarter upfront fee million toyama expense report research development year end december statement consolidated operation company enter strategic agreement bayer intend enhance company pharmaceutical resource term agreement company exclusive right puerto rico market sell distribute avelox cipro antibiotic use exclude certain topical formulation administration eye ear company pay bayer royalty generally excess percent product base sale agreement company undertake bayer commercialization activity erectile dysfunction medicine levitra bayers promotion agreement glaxosmithkline plc japanese market bayer comarket company cholesterolabsorption inhibitor zetia approve company receive record defer revenue million relate sale zetia copromotion right bayer defer revenue begin recognize regulatory approval japan zetia currently regulatory review japan certain circumstance zetia receive regulatorymarkete approval japan certain date require repay bayer agreement bayer potentially restrict company marketing product compete product agreement result company expect table content note consolidated financial statement continue sublicense right garenoxacin quinolone antibacterial agent company license toyama shortterm borrowing longterm debt commitment short longterm borrowing general shortterm borrowing consist bank loan commercial paper issue shortterm borrowing december total billion billion respectively include shortterm borrowing commercial paper outstanding december million billion respectively weight average interest rate shortterm borrowing december percent percent respectively november company issue billion aggregate principal percent senior unsecured note billion aggregate principal percent senior unsecured note interest payable semiannually net proceed offer billion issuance note rate moodys investors service inc moodys standard poor rating service interest rate payable note subject adjustment follow rate assign particular series note moodys change rating set forth interest rate payable series note initial interest rate percent note percent note plus additional interest rate set forth moodys additional interest rate moody rating rating baa bbb baa bbb baa bbb event interest rate note increase percent initial coupon rate percent percent respectively moodys subsequently upgrade rating interest rate correspondingly reduce percent percent respectively furthermore interest rate payable particular series note return percent percent respectively rate adjustment provision permanently cease apply follow downgrade moodys respectively note subsequently rate baa moodys bbb july moodys lower rating note baa accordingly interest payable note increase basis point effective december effective december interest rate payable note increase percent percent interest rate payable note increase percent percent december note rate baa moodys note redeemable company option time redemption price equal great percent principal note sum present value remain schedule payment principal interest discount rate treasury note comparable remain term plus basis point note basis point note credit facility company revolve credit facility syndicate major financial institution march company negotiate increase commitment facility billion billion change basic term preexist credit facility concurrently table content note consolidated financial statement continue increase commitment facility company terminate early separate million line credit mature outstanding balance facility time terminate exist billion credit facility mature require company maintain total debt capital ratio percent credit line available general corporate purpose management consider facility support company commercial paper borrowing borrowing credit facility draw parent company whollyowne international subsidiary accompany parent guarantee facility require compensating balance nominal commitment fee pay december million draw facility whollyowne international subsidiary fund ajca repatriation addition aforementioned credit facility company enter million credit facility fourth quarter draw december credit facility utilize whollyowne international subsidiary fund repatriation ajca credit facility require company maintain total debt total capital ratio percent borrowing payable later november fund borrow facility subsequently repay reborrowe credit facility borrowing classify shortterm borrowing company intend repay amount month addition company international subsidiary approximately million available unused line credit financial institution december commitment total rent expense amount million million million future annual minimum rental commitment noncancelable operating lease december follow million million million million million aggregate minimum lease obligation million december capital lease obligation million million include current portion longterm debt longterm debt respectively december company commitment total million relate capital expenditure financial instrument sfas derivative instrument financial hedging activity amend require derivative record balance sheet fair value accounting standard provide effective portion qualify cash flow hedge recognize income hedge item affect income change fair value derivative qualify fair value hedge change fair value hedge risk recognize occur change fair value derivative qualify hedge treatment ineffective portion qualifying hedge recognize income occur risk policy objective company expose market risk primarily change foreign currency exchange rate less extent interest rate equity price change time time company hedge selective foreign currency risk derivative currently management deem cost effective engage formulabase program hedge profit cash flow international operation derivative financial instrument companys international subsidiary purchase significant quantity inventory payable dollar manage level inventory table content note consolidated financial statement continue related payable rate inventory turnover provide natural level protection adverse change exchange rate furthermore risk adverse exchange rate change somewhat mitigated fact company international operation widespread limited basis company hedge selective foreign currency contract exposure mitigate exchange rate risk company mitigate credit risk derivative instrument deal counterpartie consider financially sound accordingly company anticipate loss nonperformance company enter derivative instrument generate trading profit table present carry value estimate fair value certain company financial instrument december estimate fair value determine base market price available dealer quote carry value financial instrument include cash cash equivalent approximate estimate fair value december carry estimate carry estimate value fair value value fair value dollar million asset shortterm investment longterm investment liabilitie shortterm borrowing current portion longterm debt longterm debt longterm investment longterm investment include noncurrent asset primarily consist debt equity security hold nonqualified trust fund long term employee benefit obligation include liability consolidated balance sheet asset fund relate liability interest rate swap contract prior march company interest rate swap arrangement effect counterparty bank arrangement utilize longterm interest rate swap contract foreignbase subsidiary company bank subsidiary company bank contract equal offset term cover master netting arrangement contract involve foreignbase subsidiary permit subsidiary prepay portion future obligation bank contract involve subsidiary permit bank prepay portion future obligation subsidiary prepayment total billion contract december term swap contract amend call phase termination swap base agree repayment schedule begin later march termination require company counterparty repay prepayment pursuant agree repayment schedule company option allow accelerate termination arrangement associate schedule repayment nominal fee february company foreignbase subsidiary subsidiary give notice counterparty intent terminate arrangement march company terminate swap agreement associate repayment respective obligor table content note consolidated financial statement continue termination arrangement material impact company statement consolidated operation shareholder equity company authorize share prefer stock consist prefer share designate series junior participate prefer stock prefer share designate percent mandatory convertible preferred stock prefer share designation determine percent mandatory convertible prefer stock shelf registration august company issue share percent mandatory convertible preferred stock prefer stock face value billion net proceed company billion deducting commission discount underwriting expense prefer stock automatically convert common share company depend average closing price company common share period immediately precede mandatory conversion date september define prospectus prefer shareholder elect convert time prior september minimum conversion ratio common share share prefer stock additionally time prior mandatory conversion date closing price company common share exceed trading day period consecutive trading day company elect cause conversion prefer stock outstanding minimum conversion ratio common share prefer share prefer stock accrue dividend annual rate percent share outstanding dividend cumulative date issuance extent company legally permit pay dividend board director declare dividend payable company pay dividend dividend payment date dividend payment date march june september december dividend pay december december company ability issue million principal security currently effective security exchange commission sec shelf registration treasury stock summary treasury share transaction year end december follow hare milli ons share balance january share issue stock incentive plan share balance december prefer share purchase right company prefer share purchase right outstanding attach presently trade company common share exercisable right exercisable person group acquire percent company common stock announce tender offer complete result ownership person group percent company common stock person group acquire percent company outstanding common stock merger business combination transaction right table content note consolidated financial statement continue entitle holder acquirer purchase common share scheringplough market value twice exercise price right exercise price right follow acquisition person group beneficial ownership percent percent company common stock board director exchange right right own acquirer exchange ratio common share twohundredth share series junior participate prefer stock right prior acquisition person group beneficial ownership percent company common stock right redeemable right option board director right expire july early redeem exchange board director authorize reduce percent threshold refer great sum percent large percentage outstanding share common stock know company beneficially own person group affiliate associate person percent follow acquisition person group beneficial ownership percent company common stock reduction adversely affect interest holder right stock incentive plan term company stock incentive plan approve company shareholder million company common share grant stock option award deferred stock unit officer certain employee company december december million option defer stock unit remain available future year grant stock incentive plan option exercise price equal market price common share grant date option expire later year date grant option grant generally year vest term grant prior generally oneyear vest term option grant vest long period range year defer stock unit payable equivalent number common share share distributable single installment equal annual installment generally commence year date award follow table summarize stock option activity past year current prior plan incentive plan approve company shareholder weight weight weight number average number average number average exercise exercise exercise option price option price option price num ber option illion outstanding january grant exercise cancel expire outstanding december exercisable december table content note consolidated financial statement continue summarize information stock option outstanding exercisable december follow stand weight average weighted weighted number remain average exercisable average term exercise number exercise exercise price range option year price option price number option llion company award defer stock unit total million unit million unit million unit respectively weight average fair value defer stock unit grant respectively insurance coverage company maintain insurance coverage deductible selfinsurance management believe adequate need current circumstance coverage reflect market condition include cost availability exist time write relationship insurance coverage selfinsurance vary accordingly result recent external event availability insurance restrictive management consider impact change continually assess good way provide insurance need future company selfinsure substantial proportion risk relate product liability segment information company reportable segment prescription pharmaceutical consumer health care animal health segment sale profit datum follow consistent company current management reporting structure prescription pharmaceutical segment discover develop manufacture market human pharmaceutical product consumer health care segment develop manufacture market overthecounter foot care sun care product primarily animal health segment discover develop manufacture market animal health product net sale segment de decem ber dollar million prescription pharmaceutical consumer health care animal health consolidate net sale table content note consolidated financial statement continue profit segment ear nde ecem ber dollar million prescription pharmaceutical consumer health care animal health corporate consolidated profitloss tax corporate include interest income expense foreign exchange gain loss headquarters expense special charge miscellaneous item accounting policy segment report describe note summary significant accounting policy corporate include special charge million include million employee termination cost million asset impairment charge increase litigation reserve million result total reserve million represent company current estimate resolve massachusetts investigation investigation disclose awp investigation state litigation disclose awp litigation note legal environmental regulatory matter estimate charge relate reportable segment follow prescription pharmaceutical million consumer health care million animal health million corporate million corporate include special charge million include million employee termination cost million asset impairment charge million closure cost primarily related exit small european research development facility estimate charge relate reportable segment follow prescription pharmaceutical million consumer health care million animal health million corporate million corporate include special charge million include million employee termination cost million provision increase litigation reserve million asset impairment charge estimate charge relate reportable segment follow prescription pharmaceutical million consumer health care million animal health million corporate million table content note consolidated financial statement continue net sale major product dollar million prescription pharmaceutical remicade pegintron nasonex clarinex aerius temodar claritin rebetol integrilin intron avelox subutex caelyx cipro elocon pharmaceutical consumer health care otc include otc claritin sale respectively foot care sun care animal health consolidate net sale net sale geographic area dollar millions united states europe canada pacific area asia latin america consolidated net sale company subsidiary country outside single foreign country france italy japan account percent consolidated net sale table content note consolidated financial statement continue past year net sale present geographic area company customer locate consolidated consolidated consolidated net sale net sale net sale net sale net sale net sale dollar million total international net sale france japan italy net sale customer consolidate consolidated consolidated net sale net sale net sale net sale net sale net sale dollar million mckesson corporation single customer mckesson corporation major pharmaceutical health care product distributor account percent consolidated net sale past year longlive asset geographic location dollar millions united states singapore ireland puerto rico total longlive asset show geographic location primarily property supplemental sale information sale product comprise percent company international sale year end december follow amo unt perce ntage dollar million nasonex otc claritin international remicade pegintron table content note consolidated financial statement continue scheringplough net sale include sale vytorin zetia market partnership merck company account joint venture equity method accounting note equity income cholesterol joint venture company disaggregate asset segment basis internal management report information present consent decree company agree fda entry consent decree resolve issue relate compliance current good manufacturing practice cgmp certain company facility new jersey puerto rico consent decree decree summary decree require company payment total million equal installment million pay addition decree require company complete revalidation program manufacturing process produce bulk active pharmaceutical ingredient finish drug product cover facility implement comprehensive cgmp work plan facility decree require foregoing complete accordance strict schedule provide possible imposition additional payment event company adhere approve schedule final completion work subject certification independent expert certification turn subject fda acceptance september company complete revalidation party certification bulk active pharmaceutical ingredient december company complete revalidation party certification finish drug product company complete significant step cgmp work plan december requirement complete accordance schedule require decree term decree provide fda notify company significant violation fda law regulation decree year period decree entry company petition court decree dissolve fda oppose company petition company report fda complete revalidation program cgmp work plan party certification work plan pende possible party expert certify completion work plan significant step fda disagree expert certification event possible fda assess additional payment permit decree describe detail general cgmp work plan contain significant step timely satisfactory completion subject payment thousand business day deadline miss payment exceed million million year payment subject overall cap million company expense additional payment assess decree incur legal environmental regulatory matter background company involve claim investigation legal proceeding company record liability contingency probable liability incur reasonably estimate company adjust liabilitie contingency reflect current good estimate probable loss minimum liability case well estimate determinable company record minimum probable range table content note consolidated financial statement continue liability expect insurance recovery consider determine amount record liability environmentalrelate matter company believe loss contingency reasonably possible probable loss estimate liability record liability reasonably possible disclosure loss contingency company review status claim investigation legal proceeding ongoing basis include related insurance coverage time time company settle resolve matter term condition management believe good interest company resolution claim investigation legal proceeding individually aggregate material adverse effect company result operation cash flow financial condition resolution include settlement matter type set forth remainder note particular investigation frequently involve fine penalty material result operation cash flow financial condition resolution matter involve injunctive administrative remedy adversely impact business exclusion government reimbursement program turn material adverse impact business future financial condition cash flow result operation assurance company prevail matter discuss remainder note settlement reach acceptable term include scope release provide absence injunctive administrative remedy adversely impact business exclusion government reimbursement program amount exceed amount reserve acceptable settlement reach assurance investigation litigation commence raise similar issue potentially expose company additional material liability outcome matter discuss investigation include commencement civil andor criminal proceeding involve imposition substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program total liability reserve reflect estimate case investigation current estimate liability final settlement adjudication matter possibly materially exceed liability record financial statement material adverse impact company financial condition cash flow operation company predict timing resolution matter outcome matter discuss remainder note record liability contingency december relate expense incur year end december material opinion management base advice legal counsel ultimate outcome matter matter discuss remainder note material impact company result operation cash flow financial condition patent matter scholl freeze away patent july orasure technology file action district court eastern district pennsylvania allege patent infringement scheringplough healthcare product sale scholl freeze away wart removal product complaint seek permanent injunction unspecified damage include treble damage investigation massachusetts investigation attorney office district massachusetts investigate broad range company sale marketing clinical trial practice program warrick pharmaceuticals warrick companys generic subsidiary investigation focus follow allege practice provide remuneration manage care table content note consolidated financial statement continue organization physician induce purchase schering pharmaceutical product offlabel marketing drug submit false pharmaceutical pricing information government purpose calculate rebate require pay medicaid program company cooperate investigation outcome investigation include commencement civil andor criminal proceeding involve imposition substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program company record liability million relate investigation investigation describe awp investigation state litigation describe awp litigation company able reach settlement current estimate resolution matter material adverse impact company result operation reflect date company able reach settlement current estimate cash flow financial condition andor business awp investigation company continue respond exist new investigation department health human services department justice state industry company practice average wholesale price awp investigation relate awp pharmaceutical company certain drug improperly exceed average price pay provider consequence result unlawful inflation certain government drug reimbursement base awp company cooperate investigation outcome investigation include imposition substantial fine penalty injunctive administrative remedy nitrodur investigation august company receive civil investigative subpoena issue office inspector general department health human service seek document concern company classification nitrodur medicaid rebate purpose company use nominal pricing bundle product sale company cooperate investigation appear subpoena number address pharmaceutical company concern inquiry issue relate payment government rebate pricing matter awp litigation company continue respond exist new litigation certain state private payor industry company practice average wholesale price awp litigation relate awp pharmaceutical company certain drug improperly exceed average price pay provider consequence result unlawful inflation certain reimbursement drug state program private payor base awp complaint allege violation federal state law include fraud medicaid fraud consumer protection violation claim majority case plaintiff seek class certification case class certify outcome litigation include substantial damage imposition substantial fine penalty injunctive administrative remedy security class action litigation federal security litigation follow company announcement fda conduct inspection company manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current good manufacturing practice lawsuit file company certain name officer lawsuit allege defendant violate federal security law allegedly fail disclose material information make material misstatement specifically allege company fail disclose allege risk new drug application clarinex delay result manufacturing issue allege company fail disclose allege depth severity table content note consolidated financial statement continue manufacturing issue complaint consolidate action district court district new jersey consolidated amend complaint file october purport represent class shareholder purchase share company stock february complaint seek compensatory damage behalf class court certify shareholder class october discovery ongoing shareholder derivative action lawsuit file district court district new jersey company certain officer director director seek damage behalf company include disgorgement trading profit defendant allegedly obtain basis material nonpublic information complaint allege failure disclose material information breach fiduciary duty director relate fda inspection investigation company pricing practice sale marketing clinical trial practice lawsuit shareholder derivative action purport assert claim behalf company shareholder derivative action pende district court district new jersey consolidate action august early stage product liability company previously disclose defendant putative class action lawsuit involve alleged claim personal injury arise plaintiff ingestion phenylpropanolaminecontaine coughcold remedy ppa product class action lawsuit plaintiff assert claim personal injury arise use laxative product seek refund purchase price laxative purchase lawsuit dismiss resolve amount pay resolve matter immaterial class action lawsuit currently exist concern ppa claim individual lawsuit involve ppa product pende company deem pende lawsuit immaterial aggregate company previously disclose defendant individual lawsuit relate recall albuterol vanceril vancenase inhaler lawsuit dismiss resolve amount pay resolve lawsuit immaterial erisa litigation march company serve putative class action complaint file district court new jersey allege company retire chairman ceo president richard jay kogan company employee saving plan plan administrator current director certain corporate officer messrs larosa moore breach fiduciary obligation certain participant plan complaint seek damage loss allegedly suffer plan complaint dismiss june plaintiff appeal august court appeal circuit reverse dismissal district court matter remand district court proceeding kdur antitrust litigation kdur scheringploughs longacting potassium chloride product supplement cardiac patient follow commencement ftc administrative proceeding describe allege class action suit file federal state court behalf direct indirect purchaser kdur scheringplough upshersmith lederle suit claim violation federal state antitrust law state statutory common law cause action suit seek unspecified damage discovery ongoing antitrust matter kdur scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle relate generic version kdur lederle upsher smith file abbreviate new drug application andas april ftc start administrative proceeding scheringplough upshersmith lederle allege anticompetitive effect settlement administrative law judge issue decision patent litigation settlement comply law respect dismiss claim company ftc staff appeal decision commission commission reverse decision table content note consolidated financial statement continue administrative law judge rule settlement violate antitrust law commission issue cease desist order impose injunctive restraint federal court appeal set aside commission rule vacate cease desist order august ftc file petition seek hear supreme court pende administrative obligation connection settlement investigation department justice attorney office eastern district pennsylvania company enter fiveyear corporate integrity agreement cia disclose note consent decree company subject obligation consent decree fda failure comply obligation cia consent decree result financial penalty matter biopharma contract dispute biopharma srl file claim civil court rome july docket chamber certain scheringplough subsidiary complaint allege company fulfill duty distribution supply agreement biopharma scheringplough subsidiary distribution scheringplough generic product manufacture biopharma hospital pharmacist france tax matter october irs auditor assert interest rate swap company enter unrelated party recharacterize loan affiliate company result additional tax liability tax year september company payment irs million income tax million interest company file refund claim tax interest irs december follow irss denial company claim refund company file suit district court district new jersey refund tax interest refund litigation currently discovery phase company tax reserve adequate cover mention payment environmental company responsibilitie environmental cleanup state local federal law include comprehensive environmental response compensation liability act commonly know superfund superfund site equivalent site state law company allege potentially responsible party prp company believe remote time material liability relation site company estimate obligation cleanup cost superfund site base information obtain federal environmental protection agency epa equivalent state agency andor study prepare independent engineer probable cost pay prps company record liability environmental assessment andor cleanup probable loss incur reasonably estimate table content report independent register public accounting firm board director shareholder scheringplough corporation audit accompany consolidated balance sheet scheringplough corporation subsidiary company december relate consolidated statement operation shareholder equity cash flow year period end december audits include financial statement schedule list item financial statement financial statement schedule responsibility company management responsibility express opinion financial statement financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position scheringplough corporation subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion financial statement schedule consider relation basic consolidated financial statement take present fairly material respect information set forth audit accordance standard public company accounting oversight board united states effectiveness company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion management assessment effectiveness company internal control financial report unqualified opinion effectiveness company internal control financial reporting deloitte touche llp parsippany new jersey february table content scheringplough corporation subsidiary quarterly datum unaudite nth march june september december llar illion cept hare figur net sale cost sale gross profit sell general administrative research development expenseincome net special charge equity incomeloss cholesterol joint venture incomeloss income taxis income tax expensebenefit net incomeloss dividend prefer share net incomeloss available common shareholder dilute earningsloss common share basic earningsloss common share dividend common share common share price high low average share outstanding diluted eps million average share outstanding basic eps million note special charge consolidated financial statement additional information relate special charge company common share list principally trade new york stock exchange approximate number holder record common share january table content item change disagreement accountant account financial disclosure applicable item control procedure management include chief executive officer chief financial officer evaluate company disclosure control procedure end period cover conclude company disclosure control procedure effective conclude change companys internal control financial reporting occur company recent fiscal quarter materially affect reasonably likely materially affect company internal control financial reporting change business environment company operate company replace upgrade number information system process ongoing year connection change company management internal control financial reporting disclosure control procedure management conclude new system effective respect control prior system example change information system occur replacement company order entry account receivable information system prescription pharmaceutical business medicaid management system management report internal control financial reporting management scheringplough corporation responsible establish maintain adequate internal control financial reporting schering plough internal control system design provide reasonable assurance company management board director preparation fair presentation publish financial statement internal control system matter design inherent limitation system determine effective provide reasonable assurance respect financial statement preparation presentation scheringplough management assess effectiveness company internal control financial reporting december make assessment management criterion set forth committee sponsor organization treadway commission coso internal control integrate framework base assessment management believe december company internal control financial report effective scheringplough independent auditor deloitte touche llp issue attestation report management assessment company internal control financial reporting report follow table content report independent register public accounting firm board director shareholder scheringplough corporation audit management assessment include accompany management report internal control financial reporting schering plough corporation subsidiary company maintain effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion management assessment opinion effectiveness company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting evaluate management assessment testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion management assessment company maintain effective internal control financial reporting december fairly state material respect base criterion establish internal control integrate framework issue committee sponsor organization treadway commission opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission table content audit accordance standard public company accounting oversight board united states consolidated financial statement financial statement schedule year end december company report date february express unqualified opinion financial statement financial statement schedule deloitte touche llp parsippany new jersey february table content iii item director executive officer registrant information concern director nominee director incorporate reference proposal election director company proxy statement annual meeting shareholder information concern executive officer include file caption executive officer registrant information concern audit committee financial expert incorporate reference audit committee report company proxy statement annual meeting shareholder information concern standard global business practice incorporate reference corporate governance material company proxy statement annual meeting shareholder item executive compensation executive compensation incorporate reference executive compensation company proxy statement annual meeting shareholder item security ownership certain beneficial owner management relate stockholder matter information concern security ownership certain beneficial owner management incorporate reference stock ownership company proxy statement annual meeting shareholder equity compensation plan information follow information relate plan equity security company issue employee director company plan equity security issue nonemployee stock incentive plan predecessor plan certain stock option transferable family member employeeoptionee relate trust table content column lumn olumn numb security remain available number security future issuance issue weightedaverage equity exercise exercise price compensation outstanding outstanding plan exclude option warrant option security reflect plan category right warrant right column equity compensat ion plan approve security holder stock incentive plan predecessor plan equity compensation plan approve security holder director stock award plan scheringplough ireland approve profit sharing scheme nonplan inducement award approve security holder restrict share total plan provide annual grant share common stock nonemployee director director defer award stock unit pay share common stock deferral period end plan permit eligible employee work scheringplough irish subsidiary enjoy tax advantage christma bonus percent percent pay pass trustee trustee purchase share common stock open market allocate share employee account euro defer year employee employee sell withdraw share allocate account year represents restrict share award pursuant restrict share agreement outside equity compensation plan adopt company hassan award restricted share commencement employment april cox award restricted share commencement employment award restrict share vest anniversary award date nonplan award authorize compensation committee board approve stockholders company item certain relationship relate transaction information concern certain relationship relate transaction incorporate reference certain transaction companys proxy statement annual meeting shareholder item principal accountant fee service information concern principal accountant fee service incorporate reference proposal ratify designation deloitte touche llp audit scheringplough book account companys proxy statement annual meeting shareholder table content item exhibit financial statement schedule follow document file report financial statement financial statement set forth item financial statement schedule merckscheringplough cholesterol partnership combine financial statement index combine statement net sale contractual expense year end december unaudite combine balance sheet december combine statement cash flow year end december unaudite combine statement partner capital year end december unaudited note combine financial statement year end december unaudite independent auditor report schedule valuation qualifying account schedule list omit applicable require table content index exhibit indicate exhibit commission file number exhibit number description location restate certificate incorpora tion incorporate reference exh ibit company period end september amend restate bylaw incorporate reference exhibit company file june right agreement company bank new incorporate reference exhibit company york date june file june form participation right agreement company incorporate reference exhibit company chase manhattan bank national association registration statement form amendment file trustee december file indenture date november company incorporate reference exhibit company bank new york trustee file november cii supplemental indenture include form note date incorporate reference exhibit company november file november ciii second supplemental indenture include form note incorporate reference exhibit company date november file november civ global senior note incorporate reference exhibit civ company year end december global senior note incorporate reference exhibit companys year end december executive incentive plan amend restate incorporate reference exhibit october companys year end december stock incentive plan amend incorporate reference exhibit company year end december bii stock incentive plan amend december incorporate reference exhibit company year end december biii amendment stock incentive plan effective incorporate reference exhibit company february year end december table content exhibit number description location stock incentive plan incorporate reference hibit company period end september cii amendment stock incentive plan effective incorporate reference exhibit february company period end march ciii amendment stock incentive plan effective incorporate reference exhibit february companys year end december stock incentive plan amend february incorporate reference exhibit company year end december employment agreement date april incorporate reference exhibit company fre hassan company file april eii employment agreement date incorporate reference exhibit company carrie cox company file eiii letter agreement date november robert incorporate reference exhibit eiii bertolini company company year end december eiv employment agreement effective change control incorporate reference exhibit eiv date november robert bertolini companys year end december scheringplough corporation letter agreement date march thomas incorporate reference exhibit company sabatino company period end march evi form employment agreement effective change incorporate reference exhibit evi control company certain executive new company year end december agreement begin june evii form employment agreement company incorporate reference exhibit eiv executive officer effective change control company year end december evii form amendment employment agreement incorporate reference exhibit company executive officer effective change company period end september control evii forms amendment employment agreement incorporate reference exhibit eiia company executive officer effective change company year end december control effective january table content exhibit number description location evii form employment agreement company incorporate reference hibit eiic executive officer effective change control company year end december incorporate prior amendment january new agreement effective begin january exi severance benefit plan amend restate effective incorporate reference exhibit exi december amendment april companys period end march exii saving advantage plan amend restate attach january amend restate director defer compensation plan incorporate reference exhibit amend october trust relate thereto company period end september fii amend restate define contribution trust incorporate reference exhibit aii company year end december supplemental executive retirement plan amend incorporate reference exhibit restate february company period end march gii amendment supplemental executive retirement plan incorporate reference exhibit effective november company period end september giii second amendment supplemental executive retirement incorporate reference exhibit plan effective october company year end december giv amend restate serp rabbi trust agreement incorporate reference exhibit company year end december directors stock award plan amend restate incorporate reference exhibit february company year end december defer compensation plan amend restate incorporate reference exhibit october company year end december form split dollar agreement relate collateral incorporate reference exhibit assignment company executive company year end december officer kii form amendment split dollar agreement relate incorporate reference exhibit collateral assignment company executive company period end march officer table content exhibit number description location retirement benefit equalization plan amend restate attach january operation management team incentive plan incorporate reference exhibit company year end december cash longterm incentive plan amend restate incorporate reference exhibit company effective january year end december longterm performance share unit incentive plan amend incorporate reference exhibit company restate effective january year end december transformational performance contingent share program incorporate reference exhibit company year end december cholesterol governance agreement date incorporate reference exhibit company company merck inc date october party signatory thereto amendment cholesterol governance agreement incorporate reference exhibit company date december company file october merck inc party signatory thereto master agreement date december incorporate reference exhibit company company merck inc party file october signatory thereto letter agreement date april relate consent incorporate reference exhibit company decree period end march distribution agreement company centocor incorporate reference exhibit companys inc date april amend year end december file amend restate director defer stock equivalency incorporate reference exhibit company program period end september summary director compensation incorporate reference exhibit company year end december computation ratio earning fix charge attach table content exhibit number description location standard global business actice cover employee incorporate reference exh ibit company include senior financial officer file september subsidiary registrant attach consent independent register public accounting firm attach independent auditor consent attach power attorney attach sarbanesoxley act section certification attach chairman board chief executive officer sarbanesoxley act section certification attach executive vice president chief financial officer sarbanesoxley act section certification attach chairman board chief executive officer sarbanesoxley act section certification attach executive vice president chief financial officer compensatory plan contract arrangement certain portion exhibit omit pursuant request confidential treatment nonpublic information file separately security exchange commission pursuant rule securities exchange act amend copy